20405238	116	Hammack SE	Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress.	Journal of molecular neuroscience 	2010	43
20664079	116	Golombek DA	Physiology of circadian entrainment.	Physiological reviews	2010	138
21350482	116	Ressler KJ	Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor.	Nature	2011	192
22530815	116	Andero R	Fear extinction and BDNF: translating animal models of PTSD to the clinic.	Genes, brain, and behavior	2012	45
22875918	199	Shi Y	Chronic-pain-associated astrocytic reaction in the spinal cord dorsal horn of human immunodeficiency virus-infected patients.	The Journal of neuroscience 	2012	36
23111107	199	Ziebell JM	Rod microglia: elongation, alignment, and coupling to form trains across the somatosensory cortex after experimental diffuse brain injury.	Journal of neuroinflammation	2012	37
23792284	199	Ji RR	Glia and pain: is chronic pain a gliopathy?	Pain	2013	125
24319664	199	Morizane A	Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate.	Stem cell reports	2013	46
24447857	199	Torres-Platas SG	Morphometric characterization of microglial phenotypes in human cerebral cortex.	Journal of neuroinflammation	2014	27
25064005	199	Rojas B	Microglia in mouse retina contralateral to experimental glaucoma exhibit multiple signs of activation in all retinal layers.	Journal of neuroinflammation	2014	32
16002223	276	Nater UM	Stress-induced changes in human salivary alpha-amylase activity -- associations with adrenergic activity.	Psychoneuroendocrinology	2006	71
17332070	276	Granger DA	Salivary alpha-amylase in biobehavioral research: recent developments and applications.	Annals of the New York Academy of Sciences	2007	89
17418498	276	Nater UM	Determinants of the diurnal course of salivary alpha-amylase.	Psychoneuroendocrinology	2007	74
19155141	276	Rohleder N	Determinants of salivary alpha-amylase in humans and methodological considerations.	Psychoneuroendocrinology	2009	57
25462896	276	Skoluda N	Intra-individual psychological and physiological responses to acute laboratory stressors of different intensity.	Psychoneuroendocrinology	2015	15
8103819	348	Poirier J	Apolipoprotein E polymorphism and Alzheimer's disease.	Lancet	1993	159
8398148	348	Rebeck GW	Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions.	Neuron	1993	161
8415756	348	Schmechel DE	Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.	Proceedings of the National Academy of Sciences of the United States of America	1993	251
8446617	348	Strittmatter WJ	Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.	Proceedings of the National Academy of Sciences of the United States of America	1993	629
8592548	348	Reiman EM	Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.	The New England journal of medicine	1996	313
10227624	348	Jack CR Jr	Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.	Neurology	1999	309
10487842	348	Lue LF	Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.	The American journal of pathology	1999	378
10681270	348	Christen Y	Oxidative stress and Alzheimer disease.	The American journal of clinical nutrition	2000	102
10762153	348	Killiany RJ	Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.	Annals of neurology	2000	150
10811879	348	Small GW	Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2000	152
10944562	348	Bookheimer SY	Patterns of brain activation in people at risk for Alzheimer's disease.	The New England journal of medicine	2000	281
11248079	348	Reiman EM	Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2001	137
11264981	348	Dietschy JM	Cholesterol metabolism in the brain.	Current opinion in lipidology	2001	159
11445259	348	Jernigan TL	Effects of age on tissues and regions of the cerebrum and cerebellum.	Neurobiology of aging	2001	186
11487050	348	Nunomura A	Oxidative damage is the earliest event in Alzheimer disease.	Journal of neuropathology and experimental neurology	2001	328
11526211	348	de Leon MJ	Prediction of cognitive decline in normal elderly subjects with 2-(18)Ffluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).	Proceedings of the National Academy of Sciences of the United States of America	2001	148
14568809	348	Lopez OL	Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2.	Archives of neurology	2003	89
14688411	348	Reiman EM	Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.	Proceedings of the National Academy of Sciences of the United States of America	2004	267
14991811	348	Gorno-Tempini ML	Cognition and anatomy in three variants of primary progressive aphasia.	Annals of neurology	2004	291
15172743	348	Raber J	ApoE genotype accounts for the vast majority of AD risk and AD pathology.	Neurobiology of aging	2004	101
15477533	348	Tang-Wai DF	Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy.	Neurology	2004	110
15623696	348	Mosconi L	MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.	Neurology	2004	85
15699382	348	Bondi MW	fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease.	Neurology	2005	114
15911795	348	Enzinger C	Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects.	Neurology	2005	71
15932949	348	Reiman EM	Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.	Proceedings of the National Academy of Sciences of the United States of America	2005	120
15987548	348	Omalu BI	Chronic traumatic encephalopathy in a National Football League player.	Neurosurgery	2005	124
16087905	348	Dickerson BC	Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD.	Neurology	2005	186
16289476	348	Scheff SW	Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment.	Neurobiology of aging	2006	162
16344478	348	Ye S	Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target.	Proceedings of the National Academy of Sciences of the United States of America	2005	75
16488378	348	Hansson O	Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.	The Lancet. Neurology	2006	307
16682537	348	Jicha GA	Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.	Archives of neurology	2006	131
16738250	348	Johnson SC	The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation.	The Journal of neuroscience 	2006	71
16782234	348	Zipser BD	Microvascular injury and blood-brain barrier leakage in Alzheimer's disease.	Neurobiology of aging	2007	84
16820298	348	Hatters DM	Apolipoprotein E structure: insights into function.	Trends in biochemical sciences	2006	143
17030756	348	Wishart HA	Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele.	Neurology	2006	61
17077159	348	Mondadori CR	Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers.	Cerebral cortex	2007	74
17470753	348	Scheff SW	Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment.	Neurology	2007	157
17474819	348	Coon KD	A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease.	The Journal of clinical psychiatry	2007	148
17485647	348	Kemppainen NM	PET amyloid ligand 11CPIB uptake is increased in mild cognitive impairment.	Neurology	2007	86
17509484	348	Shaw P	Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study.	The Lancet. Neurology	2007	89
17515542	348	Bowman GL	Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.	Neurology	2007	55
17698496	348	Lockhart A	PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis.	Brain 	2007	90
17879383	348	Sonnen JA	Pathological correlates of dementia in a longitudinal, population-based sample of aging.	Annals of neurology	2007	154
18003925	348	Mosconi L	Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism.	Proceedings of the National Academy of Sciences of the United States of America	2007	85
18054253	348	Vemuri P	Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies.	NeuroImage	2008	142
18349428	348	Calderón-Garcidueñas L	Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults.	Toxicologic pathology	2008	103
18378884	348	Vernooij MW	Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study.	Neurology	2008	117
18412267	348	Mesulam M	Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia.	Annals of neurology	2008	135
18430999	348	Reger MA	Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.	Journal of Alzheimer's disease 	2008	106
18608129	348	Brouwers N	Molecular genetics of Alzheimer's disease: an update.	Annals of medicine	2008	54
18663180	348	Cramer C	Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.	Neurology	2008	56
18691658	348	Hua X	Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects.	NeuroImage	2008	135
18723162	348	Devanand DP	Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease.	Biological psychiatry	2008	68
18801597	348	Smith CD	White matter diffusion alterations in normal women at risk of Alzheimer's disease.	Neurobiology of aging	2010	42
19076441	348	Mosconi L	Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.	Annals of the New York Academy of Sciences	2008	90
19204149	348	Palop JJ	Epilepsy and cognitive impairments in Alzheimer disease.	Archives of neurology	2009	145
19251758	348	Schuff N	MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.	Brain 	2009	166
19255410	348	Berlau DJ	APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old.	Neurology	2009	55
19319544	348	Bell RD	Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.	Acta neuropathologica	2009	186
19339712	348	Drzezga A	Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.	Neurology	2009	66
19349228	348	Langbaum JB	Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).	NeuroImage	2009	97
19584447	348	Honea RA	Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study.	Journal of Alzheimer's disease 	2009	57
19812458	348	Honea RA	Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease.	Alzheimer disease and associated disorders	2009	73
19901249	348	Migliaccio R	Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum.	Neurology	2009	57
19918254	348	Fotuhi M	Changing perspectives regarding late-life dementia.	Nature reviews. Neurology	2009	77
19923550	348	Salloway S	A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.	Neurology	2009	173
20031276	348	Rasgon NL	Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease.	Neurobiology of aging	2011	41
20065246	348	Honea RA	Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease.	Neurology	2010	47
20155424	348	Grinberg LT	Vascular pathology in the aged human brain.	Acta neuropathologica	2010	61
20231448	348	Mosconi L	Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.	Proceedings of the National Academy of Sciences of the United States of America	2010	59
20373342	348	Vemuri P	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.	Annals of neurology	2010	61
20463288	348	O'Brien JL	Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline.	Neurology	2010	69
20537952	348	Huang Y	Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease.	Trends in molecular medicine	2010	44
20538373	348	Caroli A	The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.	Neurobiology of aging	2010	46
20541837	348	Koch W	Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease.	Neurobiology of aging	2012	48
20547867	348	Chen Y	ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling.	Proceedings of the National Academy of Sciences of the United States of America	2010	77
20592257	348	Landau SM	Comparing predictors of conversion and decline in mild cognitive impairment.	Neurology	2010	153
20739645	348	Ahtiluoto S	Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study.	Neurology	2010	90
20837822	348	Baker LD	Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes.	Archives of neurology	2011	125
20847408	348	Valla J	Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene.	Journal of Alzheimer's disease 	2010	52
20876479	348	Poels MM	Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study.	Stroke	2010	76
21035308	348	Cunnane S	Brain fuel metabolism, aging, and Alzheimer's disease.	Nutrition	2011	78
21060014	348	Carmichael O	Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.	Archives of neurology	2010	72
21158978	348	Morgan D	Immunotherapy for Alzheimer's disease.	Journal of internal medicine	2011	55
21159973	348	Sheline YI	APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42.	The Journal of neuroscience 	2010	123
21283692	348	Twine NA	Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease.	PloS one	2011	79
21422459	348	Gupta VB	Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging.	Neurology	2011	44
21529702	348	Pike KE	Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.	Neuropsychologia	2011	45
21596774	348	Nelson PT	Hippocampal sclerosis in advanced age: clinical and pathological features.	Brain 	2011	69
21706175	348	Schmidt R	Heterogeneity in age-related white matter changes.	Acta neuropathologica	2011	47
21802369	348	Murray ME	Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.	The Lancet. Neurology	2011	118
21851856	348	Trachtenberg AJ	The effects of APOE on the functional architecture of the resting brain.	NeuroImage	2012	33
21955814	348	Calderón-Garcidueñas L	Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults.	Journal of Alzheimer's disease 	2012	45
21971471	348	Reiman EM	Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.	Journal of Alzheimer's disease 	2011	103
21975202	348	Jones DT	Age-related changes in the default mode network are more advanced in Alzheimer disease.	Neurology	2011	74
22169231	348	Sabuncu MR	The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects.	Cerebral cortex	2012	32
22228589	348	Zhu Y	APOE genotype alters glial activation and loss of synaptic markers in mice.	Glia	2012	38
22232206	348	Head D	Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.	Archives of neurology	2012	56
22302550	348	Rodrigue KM	β-Amyloid burden in healthy aging: regional distribution and cognitive consequences.	Neurology	2012	97
22305802	348	Sperling R	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.	The Lancet. Neurology	2012	67
22371413	348	Tan ZS	Red blood cell ω-3 fatty acid levels and markers of accelerated brain aging.	Neurology	2012	39
22409939	348	Jack CR Jr	Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.	Archives of neurology	2012	42
22457774	348	Zhao X	Disrupted small-world brain networks in moderate Alzheimer's disease: a resting-state FMRI study.	PloS one	2012	37
22517093	348	Seppälä TT	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.	Neurology	2012	37
22581847	348	Tremblay S	Sports concussions and aging: a neuroimaging investigation.	Cerebral cortex	2013	30
22613170	348	McDonald BC	Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.	Brain, behavior, and immunity	2013	33
22633529	348	Fleisher AS	Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.	Neurobiology of aging	2013	40
22637583	348	Koffie RM	Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.	Brain 	2012	62
22699906	348	Damoiseaux JS	Gender modulates the APOE ε4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels.	The Journal of neuroscience 	2012	47
22961445	348	Nordberg A	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.	European journal of nuclear medicine and molecular imaging	2013	30
22972644	348	Mielke MM	Indicators of amyloid burden in a population-based study of cognitively normal elderly.	Neurology	2012	33
22972646	348	Lo RY	Vascular burden and Alzheimer disease pathologic progression.	Neurology	2012	47
23018443	348	Soontornniyomkij V	Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers.	AIDS	2012	32
23037886	348	Irwin DJ	Neuropathologic substrates of Parkinson disease dementia.	Annals of neurology	2012	81
23100439	348	Hashimoto T	Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide.	The Journal of neuroscience 	2012	39
23153970	348	Hua X	Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials.	NeuroImage	2013	51
23238736	348	Jagust WJ	Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging.	The Journal of neuroscience 	2012	49
23240599	348	Jahanshad N	Disrupted brain networks in the aging HIV+ population.	Brain connectivity	2012	32
23243071	348	Gomperts SN	Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia.	Neurology	2013	35
23280791	348	Vemuri P	Effect of lifestyle activities on Alzheimer disease biomarkers and cognition.	Annals of neurology	2012	35
23424032	348	Knopman DS	Brain injury biomarkers are not dependent on β-amyloid in normal elderly.	Annals of neurology	2013	45
23446680	348	Jack CR Jr	Brain β-amyloid load approaches a plateau.	Neurology	2013	58
23553344	348	Rodrigue KM	Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects.	JAMA neurology	2013	41
23599929	348	Protas HD	Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease.	JAMA neurology	2013	28
23883936	348	Rhinn H	Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease.	Nature	2013	51
24132374	348	Hughes TM	Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults.	Neurology	2013	31
24145819	348	Lim AS	Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep.	JAMA neurology	2013	34
24259049	348	Hudry E	Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain.	Science translational medicine	2013	26
24269021	348	Johnson SC	Amyloid burden and neural function in people at risk for Alzheimer's Disease.	Neurobiology of aging	2014	29
24276092	348	Dean DC 3rd	Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study.	JAMA neurology	2014	46
24378418	348	Reed B	Associations between serum cholesterol levels and cerebral amyloidosis.	JAMA neurology	2014	30
24401693	348	Duan L	Stem cell derived basal forebrain cholinergic neurons from Alzheimer's disease patients are more susceptible to cell death.	Molecular neurodegeneration	2014	26
24450891	348	Salloway S	Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.	The New England journal of medicine	2014	245
24559670	348	Kanekiyo T	ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?	Neuron	2014	66
24623839	348	Yates PA	Incidence of cerebral microbleeds in preclinical Alzheimer disease.	Neurology	2014	20
24748674	348	Mormino EC	Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.	Neurology	2014	60
25155658	348	Palmqvist S	Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.	JAMA neurology	2014	44
25253756	348	Kryscio RJ	Self-reported memory complaints: implications from a longitudinal cohort with autopsies.	Neurology	2014	31
25672924	348	Wang R	Effects of vascular risk factors and APOE ε4 on white matter integrity and cognitive decline.	Neurology	2015	18
25775353	348	Jack CR Jr	Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span.	JAMA neurology	2015	49
25988462	348	Jansen WJ	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.	JAMA	2015	73
25988463	348	Ossenkoppele R	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.	JAMA	2015	36
26208959	348	Liu E	Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.	Neurology	2015	20
26214150	348	Willette AA	Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease.	JAMA neurology	2015	23
26354483	348	Jaunmuktane Z	Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy.	Nature	2015	41
26374897	348	Bailey CC	The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E.	The Journal of biological chemistry	2015	21
26374899	348	Atagi Y	Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2).	The Journal of biological chemistry	2015	25
26518018	348	Bieniek KF	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank.	Acta neuropathologica	2015	26
26564908	348	Tambini MD	ApoE4 upregulates the activity of mitochondria-associated ER membranes.	EMBO reports	2016	13
26791201	348	Theendakara V	Direct Transcriptional Effects of Apolipoprotein E.	The Journal of neuroscience 	2016	13
27025652	348	Selkoe DJ	The amyloid hypothesis of Alzheimer's disease at 25 years.	EMBO molecular medicine	2016	126
27979356	348	Irwin DJ	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.	The Lancet. Neurology	2017	7
2649245	351	Weidemann A	Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein.	Cell	1989	191
7857653	351	Saido TC	Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.	Neuron	1995	118
8073293	351	Bush AI	Rapid induction of Alzheimer A beta amyloid formation by zinc.	Science	1994	176
8626743	351	Kuo YM	Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains.	The Journal of biological chemistry	1996	141
8810256	351	Hsiao K	Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.	Science	1996	937
9126051	351	Ferguson B	Axonal damage in acute multiple sclerosis lesions.	Brain 	1997	190
10681545	351	Wang HY	beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology.	The Journal of biological chemistry	2000	144
10735393	351	Näslund J	Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.	JAMA	2000	252
10833057	351	Roof RL	Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone.	Journal of neurotrauma	2000	105
10978169	351	Walsh DM	The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain.	Biochemistry	2000	115
11145990	351	Dovey HF	Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.	Journal of neurochemistry	2001	177
11409420	351	Grabowski TJ	Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy.	Annals of neurology	2001	113
11683988	351	Selkoe DJ	Clearing the brain's amyloid cobwebs.	Neuron	2001	124
11733217	351	Butterfield DA	Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide.	Trends in molecular medicine	2001	172
11910111	351	DeMattos RB	Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.	Science	2002	105
11932745	351	Walsh DM	Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.	Nature	2002	991
11959919	351	Rapoport M	Tau is essential to beta -amyloid-induced neurotoxicity.	Proceedings of the National Academy of Sciences of the United States of America	2002	178
12084879	351	Thal DR	Phases of A beta-deposition in the human brain and its relevance for the development of AD.	Neurology	2002	398
12244078	351	Kuhlmann T	Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.	Brain 	2002	99
12702875	351	Kayed R	Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.	Science	2003	950
14643377	351	Oddo S	Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease.	Neurobiology of aging	2003	215
14970312	351	Cutler RG	Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	208
15073156	351	Caillé I	Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone.	Development	2004	85
15082135	351	Dougherty PM	Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients.	Pain	2004	90
15148385	351	Craner MJ	Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger.	Proceedings of the National Academy of Sciences of the United States of America	2004	90
15474976	351	Tuppo EE	The role of inflammation in Alzheimer's disease.	The international journal of biochemistry and cell biology	2005	127
15731448	351	Stokin GB	Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease.	Science	2005	295
15834427	351	Klyubin I	Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.	Nature medicine	2005	138
15864339	351	Gandy S	The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.	The Journal of clinical investigation	2005	101
16401735	351	Markesbery WR	Neuropathologic substrate of mild cognitive impairment.	Archives of neurology	2006	155
16541076	351	Lesné S	A specific amyloid-beta protein assembly in the brain impairs memory.	Nature	2006	803
16738244	351	Deshpande A	Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons.	The Journal of neuroscience 	2006	115
16799555	351	Bateman RJ	Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.	Nature medicine	2006	135
16837572	351	Rajendran L	Alzheimer's disease beta-amyloid peptides are released in association with exosomes.	Proceedings of the National Academy of Sciences of the United States of America	2006	227
16959815	351	Cabrejo L	Phenotype associated with APP duplication in five families.	Brain 	2006	62
17086100	351	Nicoll JA	Abeta species removal after abeta42 immunization.	Journal of neuropathology and experimental neurology	2006	108
17187063	351	Fulga TA	Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.	Nature cell biology	2007	110
17360908	351	Shankar GM	Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway.	The Journal of neuroscience 	2007	440
17430239	351	Craft S	Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.	Current Alzheimer research	2007	126
17664130	351	Butterfield DA	Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.	Free radical biology and medicine	2007	101
17785178	351	Palop JJ	Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.	Neuron	2007	321
17855343	351	Townsend M	Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway.	The Journal of biological chemistry	2007	90
17942819	351	Reger MA	Intranasal insulin improves cognition and modulates beta-amyloid in early AD.	Neurology	2008	161
17950572	351	Lockstone HE	Gene expression profiling in the adult Down syndrome brain.	Genomics	2007	58
18359102	351	Selkoe DJ	Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.	Behavioural brain research	2008	303
18417702	351	Klyubin I	Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.	The Journal of neuroscience 	2008	105
18458217	351	Bian H	CSF biomarkers in frontotemporal lobar degeneration with known pathology.	Neurology	2008	54
18953056	351	Boche D	Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.	Brain 	2008	80
19118806	351	Roher AE	Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease.	Alzheimer's and dementia 	2009	58
19228952	351	Meilandt WJ	Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.	The Journal of neuroscience 	2009	54
19433662	351	Dong Y	The common inhalational anesthetic sevoflurane induces apoptosis and increases beta-amyloid protein levels.	Archives of neurology	2009	53
19581601	351	Britschgi M	Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2009	46
19828212	351	Vogt DL	Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain.	Neurobiology of aging	2011	35
19862561	351	Hung YH	Copper in the brain and Alzheimer's disease.	Journal of biological inorganic chemistry 	2010	46
19940172	351	Cohen AD	Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.	The Journal of neuroscience 	2009	73
19951690	351	Sun B	Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease.	Cell stem cell	2009	49
20008651	351	Storandt M	Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.	Archives of neurology	2009	128
20061647	351	Murphy MP	Alzheimer's disease and the amyloid-beta peptide.	Journal of Alzheimer's disease 	2010	63
20101004	351	Hartz AM	Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease.	Molecular pharmacology	2010	63
20209079	351	Soscia SJ	The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.	PloS one	2010	147
20237263	351	Kaneko M	Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation.	The Journal of neuroscience 	2010	43
20851519	351	Haanpää M	NeuPSIG guidelines on neuropathic pain assessment.	Pain	2011	102
22017494	351	Rosen RF	Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats.	Journal of neurochemistry	2012	36
22116809	351	Hartz AM	Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.	Stroke	2012	36
22635102	351	Bush AI	The metal theory of Alzheimer's disease.	Journal of Alzheimer's disease 	2013	28
22869752	351	Sanchez PE	Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.	Proceedings of the National Academy of Sciences of the United States of America	2012	102
23525040	351	Suberbielle E	Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β.	Nature neuroscience	2013	77
23575824	351	Cohen RM	A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss.	The Journal of neuroscience 	2013	40
24524897	351	Muratore CR	The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons.	Human molecular genetics	2014	44
25253695	351	Benilova I	The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation.	The Journal of biological chemistry	2014	27
25620700	351	Matarin M	A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology.	Cell reports	2015	20
26651341	351	Head E	Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.	Current Alzheimer research	2016	13
26931567	351	Maeda S	Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice.	EMBO reports	2016	12
15561405	361	Simard M	The neurobiology of glia in the context of water and ion homeostasis.	Neuroscience	2004	107
16831965	361	Pittock SJ	Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.	Archives of neurology	2006	103
17282996	361	Roemer SF	Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.	Brain 	2007	143
17449477	361	Takahashi T	Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.	Brain 	2007	109
19096776	361	Zador Z	Role of aquaporin-4 in cerebral edema and stroke.	Handbook of experimental pharmacology	2009	58
19229993	361	Nicchia GP	Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies.	Glia	2009	55
19938104	361	Bennett JL	Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.	Annals of neurology	2009	157
20047900	361	Saadoun S	Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.	Brain 	2010	140
20639914	361	Jarius S	AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance.	Nature reviews. Neurology	2010	100
20826711	361	Shimizu J	IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum.	Neurology	2010	48
21368286	361	Popescu BF	Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications.	Neurology	2011	57
21550068	361	Jarius S	Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.	Journal of the neurological sciences	2011	41
22146605	361	Min JH	Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.	Multiple sclerosis	2012	40
22260418	361	Jarius S	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.	Journal of neuroinflammation	2012	91
22387049	361	Wolburg H	The disturbed blood-brain barrier in human glioblastoma.	Molecular aspects of medicine	2012	35
22393049	361	Phuan PW	Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays.	The Journal of biological chemistry	2012	46
22577216	361	Kitley J	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.	Brain 	2012	34
23142960	361	Jacob A	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.	Journal of neurology, neurosurgery, and psychiatry	2013	30
23486868	361	Matthews L	Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.	Neurology	2013	25
24666204	361	Jarius S	Neuromyelitis optica: clinical features, immunopathogenesis and treatment.	Clinical and experimental immunology	2014	31
24700511	361	Titulaer MJ	Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis.	Annals of neurology	2014	43
25695963	361	Kim HJ	MRI characteristics of neuromyelitis optica spectrum disorder: an international update.	Neurology	2015	32
16209725	551	Depue RA	A neurobehavioral model of affiliative bonding: implications for conceptualizing a human trait of affiliation.	The Behavioral and brain sciences	2005	98
18053631	551	Caldwell HK	Vasopressin: behavioral roles of an "original" neuropeptide.	Progress in neurobiology	2008	111
19084465	551	Skuse DH	Dopaminergic-neuropeptide interactions in the social brain.	Trends in cognitive sciences	2009	59
19341763	551	Veenema AH	Early life stress, the development of aggression and neuroendocrine and neurobiological correlates: what can we learn from animal models?	Frontiers in neuroendocrinology	2009	48
20346754	551	Insel TR	The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior.	Neuron	2010	207
20688099	551	Young KA	The neurobiology of pair bonding: insights from a socially monogamous rodent.	Frontiers in neuroendocrinology	2011	57
21840129	551	Rilling JK	Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men.	Psychoneuroendocrinology	2012	70
22079778	551	Albers HE	The regulation of social recognition, social communication and aggression: vasopressin in the social behavior neural network.	Hormones and behavior	2012	40
22326707	551	Zink CF	Human neuroimaging of oxytocin and vasopressin in social cognition.	Hormones and behavior	2012	42
22840551	551	Atzil S	Synchrony and specificity in the maternal and the paternal brain: relations to oxytocin and vasopressin.	Journal of the American Academy of Child and Adolescent Psychiatry	2012	31
24157401	551	Rilling JK	Sex differences in the neural and behavioral response to intranasal oxytocin and vasopressin during human social interaction.	Psychoneuroendocrinology	2014	51
10071091	590	Francis PT	The cholinergic hypothesis of Alzheimer's disease: a review of progress.	Journal of neurology, neurosurgery, and psychiatry	1999	160
14693108	590	McKeith I	Dementia with Lewy bodies.	The Lancet. Neurology	2004	104
15687315	590	Sink KM	Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.	JAMA	2005	108
16081444	590	Kaduszkiewicz H	Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.	BMJ	2005	74
16854944	590	Engler H	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.	Brain 	2006	150
18063409	590	Chen R	The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee.	Clinical neurophysiology 	2008	61
18726789	590	Eaton DL	Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment.	Critical reviews in toxicology	2008	66
23658161	590	Moran RJ	Free energy, precision and learning: the role of cholinergic neuromodulation.	The Journal of neuroscience 	2013	50
9920498	627	Quigley HA	Neuronal death in glaucoma.	Progress in retinal and eye research	1999	172
11927139	627	Karege F	Decreased serum brain-derived neurotrophic factor levels in major depressed patients.	Psychiatry research	2002	183
12008958	627	Fujimura H	Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation.	Thrombosis and haemostasis	2002	84
12052919	627	Simerly RB	Wired for reproduction: organization and development of sexually dimorphic circuits in the mammalian forebrain.	Annual review of neuroscience	2002	177
12086747	627	Cotman CW	Exercise: a behavioral intervention to enhance brain health and plasticity.	Trends in neurosciences	2002	402
12553913	627	Egan MF	The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.	Cell	2003	721
12851636	627	Weickert CS	Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia.	Molecular psychiatry	2003	106
12890761	627	Hariri AR	Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance.	The Journal of neuroscience 	2003	248
15128854	627	Chen ZY	Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons.	The Journal of neuroscience 	2004	174
15145621	627	Hashimoto K	Critical role of brain-derived neurotrophic factor in mood disorders.	Brain research. Brain research reviews	2004	76
15537879	627	Pezawas L	The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology.	The Journal of neuroscience 	2004	240
15610974	627	Morrison JC	Understanding mechanisms of pressure-induced optic nerve damage.	Progress in retinal and eye research	2005	67
15644983	627	Campbell S	The role of the hippocampus in the pathophysiology of major depression.	Journal of psychiatry and neuroscience 	2004	123
15741046	627	Mattson MP	Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems.	The Journal of nutritional biochemistry	2005	93
15768049	627	Szeszko PR	Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation.	Molecular psychiatry	2005	99
16680163	627	Kleim JA	BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex.	Nature neuroscience	2006	114
16818862	627	Ho BC	Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers.	Archives of general psychiatry	2006	62
17404118	627	Frodl T	Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression.	Archives of general psychiatry	2007	87
17504103	627	Arai AC	Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior.	Current drug targets	2007	58
17522015	627	Bredy TW	Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear.	Learning and memory	2007	164
17762509	627	Schmidt HD	The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior.	Behavioural pharmacology	2007	172
18347599	627	Pezawas L	Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression.	Molecular psychiatry	2008	68
18504424	627	Hamilton JP	Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies.	Molecular psychiatry	2008	75
18632683	627	Mellios N	A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex.	Human molecular genetics	2008	81
18817811	627	Cirulli F	Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates.	Neuroscience and biobehavioral reviews	2009	50
18845611	627	Cheeran B	A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS.	The Journal of physiology	2008	149
19153574	627	Gatt JM	Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety.	Molecular psychiatry	2009	129
19335934	627	Montag C	The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression.	Psychological medicine	2009	47
19358879	627	Casey BJ	Brain-derived neurotrophic factor as a model system for examining gene by environment interactions across development.	Neuroscience	2009	46
19621014	627	Taliaz D	Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis.	Molecular psychiatry	2010	88
19745020	627	McHughen SA	BDNF val66met polymorphism influences motor system function in the human brain.	Cerebral cortex	2010	48
19923361	627	Seifert T	Endurance training enhances BDNF release from the human brain.	American journal of physiology. Regulatory, integrative and comparative physiology	2010	67
19940189	627	Sasaki M	BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury.	The Journal of neuroscience 	2009	50
20194826	627	Keller S	Increased BDNF promoter methylation in the Wernicke area of suicide subjects.	Archives of general psychiatry	2010	63
20392958	627	Erickson KI	Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume.	The Journal of neuroscience 	2010	79
20702043	627	Bus BA	Determinants of serum brain-derived neurotrophic factor.	Psychoneuroendocrinology	2011	41
20705090	627	Chiu CT	Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.	Pharmacology and therapeutics	2010	54
20726844	627	Johansson BB	Current trends in stroke rehabilitation. A review with focus on brain plasticity.	Acta neurologica Scandinavica	2011	36
20965453	627	Antal A	Brain-derived neurotrophic factor (BDNF) gene polymorphisms shape cortical plasticity in humans.	Brain stimulation	2010	48
21081796	627	Zoladz JA	The effect of physical activity on the brain derived neurotrophic factor: from animal to human studies.	Journal of physiology and pharmacology 	2010	44
21195196	627	Chiang MC	BDNF gene effects on brain circuitry replicated in 455 twins.	NeuroImage	2011	39
21368041	627	Pruunsild P	Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene.	The Journal of neuroscience 	2011	60
21531985	627	Erickson KI	The aging hippocampus: interactions between exercise, depression, and BDNF.	The Neuroscientist 	2012	56
21672499	627	Mondelli V	Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume.	The Journal of clinical psychiatry	2011	38
22218094	627	Bath KG	BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity.	Neuropsychopharmacology 	2012	38
22750524	627	Intlekofer KA	Exercise counteracts declining hippocampal function in aging and Alzheimer's disease.	Neurobiology of disease	2013	51
22847651	627	Vivar C	All about running: synaptic plasticity, growth factors and adult hippocampal neurogenesis.	Current topics in behavioral neurosciences	2013	55
23481688	627	Hjorth E	Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers.	Journal of Alzheimer's disease 	2013	27
23674053	627	Lu B	BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases.	Nature reviews. Neuroscience	2013	95
23720292	627	Gomez-Pinilla F	The influence of exercise on cognitive abilities.	Comprehensive Physiology	2013	37
23739121	627	Ikegame T	DNA methylation of the BDNF gene and its relevance to psychiatric disorders.	Journal of human genetics	2013	31
24048383	627	Anastasia A	Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction.	Nature communications	2013	29
24733968	627	Duman RS	Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections.	Dialogues in clinical neuroscience	2014	35
24912158	627	Gideons ES	Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.	Proceedings of the National Academy of Sciences of the United States of America	2014	38
25266124	627	Fernandes BS	Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications.	Molecular psychiatry	2015	18
25330738	627	Darcq E	MicroRNA-30a-5p in the prefrontal cortex controls the transition from moderate to excessive alcohol consumption.	Molecular psychiatry	2015	18
25451089	627	Leal G	Regulation of hippocampal synaptic plasticity by BDNF.	Brain research	2015	34
25582786	627	Duman CH	Spine synapse remodeling in the pathophysiology and treatment of depression.	Neuroscience letters	2015	21
25772071	627	Young JE	Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells.	Cell stem cell	2015	18
17156911	706	Venneti S	The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging.	Progress in neurobiology	2006	72
18093844	706	Fujita M	Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation.	NeuroImage	2008	61
19077109	706	Cosenza-Nashat M	Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.	Neuropathology and applied neurobiology	2009	60
21149489	706	Owen DR	Mixed-affinity binding in humans with 18-kDa translocator protein ligands.	Journal of nuclear medicine 	2011	62
22968319	706	Kreisl WC	A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation.	Journal of cerebral blood flow and metabolism 	2013	46
23775979	706	Kreisl WC	In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.	Brain 	2013	54
24397957	706	Karlstetter M	Translocator protein (18 kDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis.	Journal of neuroinflammation	2014	25
25385788	706	Kenk M	Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with 18F-FEPPA.	Schizophrenia bulletin	2015	35
25629589	706	Setiawan E	Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes.	JAMA psychiatry	2015	55
25766898	706	Lyoo CH	Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein.	Journal of nuclear medicine 	2015	18
26384512	706	Stefaniak J	Imaging of neuroinflammation in dementia: a review.	Journal of neurology, neurosurgery, and psychiatry	2016	11
27117856	706	Yokokura M	Depiction of microglial activation in aging and dementia: Positron emission tomography with &lt;sup&gt;11&lt;/sup&gt;CDPA713 versus &lt;sup&gt;11&lt;/sup&gt;C( R)PK11195.	Journal of cerebral blood flow and metabolism 	2017	8
27609240	706	Hafizi S	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With &lt;sup&gt;18&lt;/sup&gt;FFEPPA.	The American journal of psychiatry	2017	7
19211719	717	Ainslie PN	Integration of cerebrovascular CO2 reactivity and chemoreflex control of breathing: mechanisms of regulation, measurement, and interpretation.	American journal of physiology. Regulatory, integrative and comparative physiology	2009	88
20133432	717	Hodges MR	The role of medullary serotonin (5-HT) neurons in respiratory control: contributions to eupneic ventilation, CO2 chemoreception, and thermoregulation.	Journal of applied physiology	2010	45
21637258	717	Turner SL	Ultra-prolonged activation of CO2-sensing neurons disorients mosquitoes.	Nature	2011	41
22495584	717	Willie CK	Regional brain blood flow in man during acute changes in arterial blood gases.	The Journal of physiology	2012	84
23719379	717	DeGennaro M	orco mutant mosquitoes lose strong preference for humans and are not repelled by volatile DEET.	Nature	2013	62
1549228	759	Arriagada PV	Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease.	Neurology	1992	441
1822725	759	Arnold SE	The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease.	Cerebral cortex	1991	232
2358525	759	West MJ	Unbiased stereological estimation of the number of neurons in the human hippocampus.	The Journal of comparative neurology	1990	180
3760943	759	Zola-Morgan S	Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus.	The Journal of neuroscience 	1986	169
8756452	759	Rempel-Clower NL	Three cases of enduring memory impairment after bilateral damage limited to the hippocampal formation.	The Journal of neuroscience 	1996	123
9626555	759	De Kloet ER	Brain corticosteroid receptor balance in health and disease.	Endocrine reviews	1998	344
9861045	759	Yrjänheikki J	Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.	Proceedings of the National Academy of Sciences of the United States of America	1998	205
9952257	759	Bragin A	Hippocampal and entorhinal cortex high-frequency oscillations (100--500 Hz) in human epileptic brain and in kainic acid--treated rats with chronic seizures.	Epilepsia	1999	128
12434059	759	Cohen I	On the origin of interictal activity in human temporal lobe epilepsy in vitro.	Science	2002	196
12450487	759	Avoli M	Network and pharmacological mechanisms leading to epileptiform synchronization in the limbic system in vitro.	Progress in neurobiology	2002	102
12495631	759	Lee AK	Memory of sequential experience in the hippocampus during slow wave sleep.	Neuron	2002	257
16682538	759	Apostolova LG	Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps.	Archives of neurology	2006	122
16872686	759	Izquierdo I	Different molecular cascades in different sites of the brain control memory consolidation.	Trends in neurosciences	2006	71
17018552	759	Apostolova LG	3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease.	Brain 	2006	92
17986679	759	Ballmaier M	Hippocampal morphology and distinguishing late-onset from early-onset elderly depression.	The American journal of psychiatry	2008	55
18356518	759	Bakker A	Pattern separation in the human hippocampal CA3 and dentate gyrus.	Science	2008	232
18375977	759	Sicotte NL	Regional hippocampal atrophy in multiple sclerosis.	Brain 	2008	71
18840532	759	Yushkevich PA	A high-resolution computational atlas of the human hippocampus from postmortem magnetic resonance imaging at 9.4 T.	NeuroImage	2009	51
18988639	759	Frisoni GB	Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla.	Brain 	2008	51
19736350	759	Schobel SA	Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders.	Archives of general psychiatry	2009	112
20143386	759	Apostolova LG	3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI.	Human brain mapping	2010	42
20194830	759	Wang Z	Magnetic resonance imaging of hippocampal subfields in posttraumatic stress disorder.	Archives of general psychiatry	2010	58
20938031	759	Kerchner GA	Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI.	Neurology	2010	50
21123571	759	Ibarz JM	Emergent dynamics of fast ripples in the epileptic hippocampus.	The Journal of neuroscience 	2010	49
21164173	759	Lacy JW	Distinct pattern separation related transfer functions in human CA3/dentate and CA1 revealed using high-resolution fMRI and variable mnemonic similarity.	Learning and memory	2011	77
21484934	759	Duncan K	Evidence for area CA1 as a match/mismatch detector: a high-resolution fMRI study of the human hippocampus.	Hippocampus	2012	50
21775513	759	Chen J	Associative retrieval processes in the human medial temporal lobe: hippocampal retrieval success and CA1 mismatch detection.	Learning and memory	2011	35
21907247	759	Schmidt B	Disambiguating the similar: the dentate gyrus and pattern separation.	Behavioural brain research	2012	42
22021324	759	Noetzel MJ	Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.	Molecular pharmacology	2012	50
22312444	759	Liu L	Trans-synaptic spread of tau pathology in vivo.	PloS one	2012	258
22331913	759	Teicher MH	Childhood maltreatment is associated with reduced volume in the hippocampal subfields CA3, dentate gyrus, and subiculum.	Proceedings of the National Academy of Sciences of the United States of America	2012	104
22440643	759	Wisse LE	Subfields of the hippocampal formation at 7 T MRI: in vivo volumetric assessment.	NeuroImage	2012	39
22573677	759	Libby LA	Differential connectivity of perirhinal and parahippocampal cortices within human hippocampal subregions revealed by high-resolution functional imaging.	The Journal of neuroscience 	2012	56
22652019	759	Boldrini M	Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression.	Biological psychiatry	2012	57
22885059	759	Schapiro AC	Shaping of object representations in the human medial temporal lobe based on temporal regularities.	Current biology 	2012	66
23415948	759	Winterburn JL	A novel in vivo atlas of human hippocampal subfields using high-resolution 3 T magnetic resonance imaging.	NeuroImage	2013	44
23428745	759	Lavenex P	Building hippocampal circuits to learn and remember: insights into the development of human memory.	Behavioural brain research	2013	32
23583108	759	Schobel SA	Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.	Neuron	2013	84
23692496	759	Blümcke I	International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods.	Epilepsia	2013	40
24443091	759	Tang X	Shape abnormalities of subcortical and ventricular structures in mild cognitive impairment and Alzheimer's disease: detecting, quantifying, and predicting.	Human brain mapping	2014	24
24888442	759	Schlichting ML	CA1 subfield contributions to memory integration and inference.	Hippocampus	2014	25
25127742	759	Haukvik UK	In vivo hippocampal subfield volumes in schizophrenia and bipolar disorder.	Biological psychiatry	2015	16
25596463	759	Yushkevich PA	Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: towards a harmonized segmentation protocol.	NeuroImage	2015	31
25611508	759	Montagne A	Blood-brain barrier breakdown in the aging human hippocampus.	Neuron	2015	122
26135716	759	Buzsáki G	Hippocampal sharp wave-ripple: A cognitive biomarker for episodic memory and planning.	Hippocampus	2015	56
27602521	759	Takeuchi T	Locus coeruleus and dopaminergic consolidation of everyday memory.	Nature	2016	12
8090221	1020	Tsai LH	p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5.	Nature	1994	184
11163260	1020	Niethammer M	NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein.	Neuron	2000	129
12796778	1020	Toyo-oka K	14-3-3epsilon is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome.	Nature genetics	2003	95
15056716	1020	Wang Q	Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5.	The Journal of neuroscience 	2004	116
17241267	1020	Wang JZ	Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.	The European journal of neuroscience	2007	107
17610816	1020	Qu D	Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease.	Neuron	2007	63
18194444	1020	Iqbal K	Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.	Journal of cellular and molecular medicine	2008	50
20473298	1020	Huang E	The role of Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphorylation in neuronal death.	Nature cell biology	2010	42
21844361	1020	Qu J	S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta-amyloid peptide.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
23142263	1020	Shukla V	Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.	Archives of medical research	2012	33
10759066	1137	Paterson D	Neuronal nicotinic receptors in the human brain.	Progress in neurobiology	2000	111
12151749	1137	Picciotto MR	Effect of nicotine and nicotinic receptors on anxiety and depression.	Neuroreport	2002	95
15809354	1137	Saeed RW	Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation.	The Journal of experimental medicine	2005	113
15858066	1137	Hurst RS	A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.	The Journal of neuroscience 	2005	138
17597586	1137	Gotti C	Heterogeneity and complexity of native brain nicotinic receptors.	Biochemical pharmacology	2007	85
17825262	1137	Grady SR	The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.	Biochemical pharmacology	2007	105
19126755	1137	Albuquerque EX	Mammalian nicotinic acetylcholine receptors: from structure to function.	Physiological reviews	2009	366
20331614	1137	Rollema H	Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.	British journal of pharmacology	2010	54
20400469	1137	Jackson KJ	Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice.	The Journal of pharmacology and experimental therapeutics	2010	57
21468359	1137	Brams M	A structural and mutagenic blueprint for molecular recognition of strychnine and d-tubocurarine by different cys-loop receptors.	PLoS biology	2011	36
21741954	1137	Wallace TL	Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.	Biochemical pharmacology	2011	44
21795541	1137	McGranahan TM	α4β2 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief.	The Journal of neuroscience 	2011	40
23143843	1137	Picciotto MR	Molecular mechanisms underlying behaviors related to nicotine addiction.	Cold Spring Harbor perspectives in medicine	2013	45
23641218	1137	Hendrickson LM	Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence.	Frontiers in psychiatry	2013	29
25460185	1137	Zoli M	Diversity of native nicotinic receptor subtypes in mammalian brain.	Neuropharmacology	2015	27
25639674	1137	Dineley KT	Nicotinic ACh receptors as therapeutic targets in CNS disorders.	Trends in pharmacological sciences	2015	39
12814859	1267	Hof PR	Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia.	Biological psychiatry	2003	80
12881607	1267	Jeong SW	Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage.	Stroke	2003	76
18558866	1267	Nave KA	Axon-glial signaling and the glial support of axon function.	Annual review of neuroscience	2008	170
20398362	1267	Jang S	Functional neural differentiation of human adipose tissue-derived stem cells using bFGF and forskolin.	BMC cell biology	2010	42
7556170	1268	Galiègue S	Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.	European journal of biochemistry	1995	256
8819477	1268	Showalter VM	Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.	The Journal of pharmacology and experimental therapeutics	1996	127
9204917	1268	Glass M	Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.	The Journal of neuroscience 	1997	116
11164622	1268	Pertwee RG	Cannabinoid receptors and pain.	Progress in neurobiology	2001	104
12461523	1268	Kathuria S	Modulation of anxiety through blockade of anandamide hydrolysis.	Nature medicine	2003	386
15728830	1268	Ramírez BG	Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.	The Journal of neuroscience 	2005	127
16467563	1268	Eggan SM	Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis.	Cerebral cortex	2007	80
16570099	1268	Pertwee RG	The pharmacology of cannabinoid receptors and their ligands: an overview.	International journal of obesity	2006	69
17115043	1268	Robbe D	Cannabinoids reveal importance of spike timing coordination in hippocampal function.	Nature neuroscience	2006	110
17245363	1268	Thomas A	Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.	British journal of pharmacology	2007	83
18482430	1268	Pertwee RG	Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.	Addiction biology	2008	52
18606950	1268	Eggan SM	Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia.	Archives of general psychiatry	2008	60
19285266	1268	Moreira FA	Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.	Best practice and research. Clinical endocrinology and metabolism	2009	48
21747398	1268	Hirvonen J	Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers.	Molecular psychiatry	2012	87
22669173	1268	Schacht JP	Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users.	Neuropsychopharmacology 	2012	30
22688188	1268	Gunduz-Cinar O	Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.	Molecular psychiatry	2013	80
23670490	1268	Neumeister A	Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study.	Molecular psychiatry	2013	49
24076098	1268	Galve-Roperh I	Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation.	Progress in lipid research	2013	31
24633558	1268	Battistella G	Long-term effects of cannabis on brain structure.	Neuropsychopharmacology 	2014	31
25981172	1268	Jenniches I	Anxiety, Stress, and Fear Response in Mice With Reduced Endocannabinoid Levels.	Biological psychiatry	2016	18
26068727	1268	Morena M	Neurobiological Interactions Between Stress and the Endocannabinoid System.	Neuropsychopharmacology 	2016	31
15199405	1270	Dezawa M	Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation.	The Journal of clinical investigation	2004	107
16254185	1270	Kokoeva MV	Neurogenesis in the hypothalamus of adult mice: potential role in energy balance.	Science	2005	169
16330757	1270	Munoz JR	Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice.	Proceedings of the National Academy of Sciences of the United States of America	2005	90
21087953	1270	Talcott KE	Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment.	Investigative ophthalmology and visual science	2011	77
22011653	1270	Krencik R	Directed differentiation of functional astroglial subtypes from human pluripotent stem cells.	Nature protocols	2011	45
22085254	1270	Hawryluk GW	An in vivo characterization of trophic factor production following neural precursor cell or bone marrow stromal cell transplantation for spinal cord injury.	Stem cells and development	2012	32
22182585	1270	Wen R	CNTF and retina.	Progress in retinal and eye research	2012	43
22875916	1270	Lavisse S	Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging.	The Journal of neuroscience 	2012	47
11381111	1312	Egan MF	Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia.	Proceedings of the National Academy of Sciences of the United States of America	2001	543
11743939	1312	Weinberger DR	Prefrontal neurons and the genetics of schizophrenia.	Biological psychiatry	2001	111
11925305	1312	Malhotra AK	A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition.	The American journal of psychiatry	2002	125
12595695	1312	Zubieta JK	COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.	Science	2003	214
12963670	1312	Goldberg TE	Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia.	Archives of general psychiatry	2003	148
14702260	1312	Diamond A	Genetic and neurochemical modulation of prefrontal cognitive functions in children.	The American journal of psychiatry	2004	78
15190105	1312	Tunbridge EM	Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex.	The Journal of neuroscience 	2004	121
15242692	1312	Goldberg TE	Genes and the parsing of cognitive processes.	Trends in cognitive sciences	2004	85
15457404	1312	Chen J	Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain.	American journal of human genetics	2004	348
15821730	1312	Meyer-Lindenberg A	Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype.	Nature neuroscience	2005	115
16611807	1312	Bertolino A	Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain.	The Journal of neuroscience 	2006	76
16786032	1312	Meyer-Lindenberg A	Impact of complex genetic variation in COMT on human brain function.	Molecular psychiatry	2006	101
16818870	1312	Brody AL	Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens.	Archives of general psychiatry	2006	72
16950222	1312	Bertolino A	Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype.	Biological psychiatry	2006	61
16984965	1312	Abdolmaleky HM	Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder.	Human molecular genetics	2006	108
17063156	1312	Apud JA	Tolcapone improves cognition and cortical information processing in normal human subjects.	Neuropsychopharmacology 	2007	71
17146014	1312	Drabant EM	Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation.	Archives of general psychiatry	2006	82
17636131	1312	Tan HY	Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function.	Proceedings of the National Academy of Sciences of the United States of America	2007	60
17726000	1312	Tan HY	Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia.	Cerebral cortex	2007	67
17913879	1312	Frank MJ	Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning.	Proceedings of the National Academy of Sciences of the United States of America	2007	163
18057197	1312	Tan HY	Catechol-O-methyltransferase Val158Met modulation of prefrontal-parietal-striatal brain systems during arithmetic and temporal transformations in working memory.	The Journal of neuroscience 	2007	56
18160646	1312	Boettiger CA	Immediate reward bias in humans: fronto-parietal networks and a role for the catechol-O-methyltransferase 158(Val/Val) genotype.	The Journal of neuroscience 	2007	101
18317466	1312	Slifstein M	COMT genotype predicts cortical-limbic D1 receptor availability measured with 11CNNC112 and PET.	Molecular psychiatry	2008	57
18497887	1312	Tan HY	Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans.	The Journal of clinical investigation	2008	55
18620336	1312	Durstewitz D	The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia.	Biological psychiatry	2008	103
19104049	1312	Dreher JC	Variation in dopamine genes influences responsivity of the human reward system.	Proceedings of the National Academy of Sciences of the United States of America	2009	108
19175757	1312	Lonsdorf TB	Genetic gating of human fear learning and extinction: possible implications for gene-environment interaction in anxiety disorder.	Psychological science	2009	65
21471363	1312	Jacobs E	Estrogen shapes dopamine-dependent cognitive processes: implications for women's health.	The Journal of neuroscience 	2011	69
21508242	1312	Doll BB	Dopaminergic genes predict individual differences in susceptibility to confirmation bias.	The Journal of neuroscience 	2011	52
21543598	1312	Ursini G	Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity.	The Journal of neuroscience 	2011	51
22815523	1312	Stice E	Multilocus genetic composite reflecting dopamine signaling capacity predicts reward circuitry responsivity.	The Journal of neuroscience 	2012	44
25080285	1312	Nombela C	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.	Brain 	2014	24
8673487	1351	Starr A	Auditory neuropathy.	Brain 	1996	135
18835452	1351	Stoodley CJ	Functional topography in the human cerebellum: a meta-analysis of neuroimaging studies.	NeuroImage	2009	319
20152963	1351	Stoodley CJ	Evidence for topographic organization in the cerebellum of motor control versus cognitive and affective processing.	Cortex; a journal devoted to the study of the nervous system and behavior	2010	187
21907811	1351	Stoodley CJ	Functional topography of the cerebellum for motor and cognitive tasks: an fMRI study.	NeuroImage	2012	144
21975446	1351	Donchin O	Cerebellar regions involved in adaptation to force field and visuomotor perturbation.	Journal of neurophysiology	2012	41
25406224	1351	Grimaldi G	Cerebellar Transcranial Direct Current Stimulation (ctDCS): A Novel Approach to Understanding Cerebellar Function in Health and Disease.	The Neuroscientist 	2016	19
25485684	1351	Johansson JU	Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models.	The Journal of clinical investigation	2015	29
25609685	1351	Marko MK	Behavioural and neural basis of anomalous motor learning in children with autism.	Brain 	2015	15
26315980	1351	Sarpal DK	Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment.	The American journal of psychiatry	2016	14
12559841	1385	Nestler EJ	Common molecular and cellular substrates of addiction and memory.	Neurobiology of learning and memory	2002	86
15013227	1385	Nguyen PV	Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases.	Progress in neurobiology	2003	88
16477009	1385	Amadoro G	NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation.	Proceedings of the National Academy of Sciences of the United States of America	2006	66
17553428	1385	Cheng HY	microRNA modulation of circadian-clock period and entrainment.	Neuron	2007	197
17720160	1385	Hannila SS	The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury.	Experimental neurology	2008	74
18457678	1385	Williams CM	Blueberry-induced changes in spatial working memory correlate with changes in hippocampal CREB phosphorylation and brain-derived neurotrophic factor (BDNF) levels.	Free radical biology and medicine	2008	61
18940959	1385	Crews FT	Mechanisms of neurodegeneration and regeneration in alcoholism.	Alcohol and alcoholism	2009	147
18982459	1385	Sancho-Pelluz J	Photoreceptor cell death mechanisms in inherited retinal degeneration.	Molecular neurobiology	2008	78
19428444	1385	Lebesgue D	Estradiol rescues neurons from global ischemia-induced cell death: multiple cellular pathways of neuroprotection.	Steroids	2009	55
20168088	1385	Carloni S	Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia.	Autophagy	2010	46
20624818	1385	Laneve P	A minicircuitry involving REST and CREB controls miR-9-2 expression during human neuronal differentiation.	Nucleic acids research	2010	49
21508516	1385	O'Donovan A	Transcriptional control of monocyte gene expression in post-traumatic stress disorder.	Disease markers	2011	39
22960213	1385	Lipovich L	Activity-dependent human brain coding/noncoding gene regulatory networks.	Genetics	2012	36
24636259	1385	Cheng TL	MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex.	Developmental cell	2014	49
8840086	1392	Meaney MJ	Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress.	Developmental neuroscience	1996	114
9854171	1392	Arborelius L	The role of corticotropin-releasing factor in depression and anxiety disorders.	The Journal of endocrinology	1999	215
10200738	1392	Baker DG	Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder.	The American journal of psychiatry	1999	96
10918705	1392	Heim C	Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood.	JAMA	2000	316
11041447	1392	Challis JRG	Endocrine and paracrine regulation of birth at term and preterm.	Endocrine reviews	2000	153
11282691	1392	Heim C	Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse.	The American journal of psychiatry	2001	131
11356984	1392	Sarnyai Z	The role of corticotropin-releasing factor in drug addiction.	Pharmacological reviews	2001	103
11430844	1392	Heim C	The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies.	Biological psychiatry	2001	456
11689280	1392	Weinstock M	Alterations induced by gestational stress in brain morphology and behaviour of the offspring.	Progress in neurobiology	2001	102
11920153	1392	Gold PW	Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states.	Molecular psychiatry	2002	225
12047726	1392	Viau V	Functional cross-talk between the hypothalamic-pituitary-gonadal and -adrenal axes.	Journal of neuroendocrinology	2002	89
12079865	1392	Jéquier E	Leptin signaling, adiposity, and energy balance.	Annals of the New York Academy of Sciences	2002	119
12220880	1392	Avishai-Eliner S	Stressed-out, or in (utero)?	Trends in neurosciences	2002	104
12377295	1392	Tsigos C	Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress.	Journal of psychosomatic research	2002	278
12597862	1392	Cowley MA	The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis.	Neuron	2003	282
12605072	1392	Koob GF	Alcoholism: allostasis and beyond.	Alcoholism, clinical and experimental research	2003	236
12832253	1392	Capuron L	Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.	The American journal of psychiatry	2003	76
12975524	1392	Dallman MF	Chronic stress and obesity: a new view of "comfort food".	Proceedings of the National Academy of Sciences of the United States of America	2003	251
15919579	1392	Wadhwa PD	Psychoneuroendocrine processes in human pregnancy influence fetal development and health.	Psychoneuroendocrinology	2005	83
15944068	1392	Weinstock M	The potential influence of maternal stress hormones on development and mental health of the offspring.	Brain, behavior, and immunity	2005	109
15946990	1392	Ito N	Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol.	FASEB journal 	2005	91
15996533	1392	Swaab DF	The stress system in the human brain in depression and neurodegeneration.	Ageing research reviews	2005	133
16162953	1392	Mawdsley JE	Psychological stress in IBD: new insights into pathogenic and therapeutic implications.	Gut	2005	77
16166805	1392	Elenkov IJ	Cytokine dysregulation, inflammation and well-being.	Neuroimmunomodulation	2005	86
16472586	1392	Dinan TG	Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?	Gastroenterology	2006	111
16876134	1392	Funk CK	Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats.	Biological psychiatry	2007	140
16918397	1392	Hauger RL	Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.	CNS and neurological disorders drug targets	2006	100
16930158	1392	Koob GF	The neurobiology of addiction: a neuroadaptational view relevant for diagnosis.	Addiction	2006	106
17115806	1392	Davis M	Neural systems involved in fear and anxiety measured with fear-potentiated startle.	The American psychologist	2006	147
17197073	1392	Slominski A	Differential expression of HPA axis homolog in the skin.	Molecular and cellular endocrinology	2007	57
17524488	1392	Bao AM	The stress system in depression and neurodegeneration: focus on the human hypothalamus.	Brain research reviews	2008	84
17825799	1392	Heim C	The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.	Biological psychiatry	2008	64
18275977	1392	Nieuwenhuizen AG	The hypothalamic-pituitary-adrenal-axis in the regulation of energy balance.	Physiology and behavior	2008	59
18339361	1392	Tyrka AR	Childhood parental loss and adult hypothalamic-pituitary-adrenal function.	Biological psychiatry	2008	62
18602762	1392	Heim C	The link between childhood trauma and depression: insights from HPA axis studies in humans.	Psychoneuroendocrinology	2008	258
18991954	1392	Sinha R	Chronic stress, drug use, and vulnerability to addiction.	Annals of the New York Academy of Sciences	2008	288
19406581	1392	Lopez-Duran NL	Hypothalamic-pituitary-adrenal axis dysregulation in depressed children and adolescents: a meta-analysis.	Psychoneuroendocrinology	2009	75
19571587	1392	Papadimitriou A	Regulation of the hypothalamic-pituitary-adrenal axis.	Neuroimmunomodulation	2009	47
19575614	1392	Holsboer F	Stress hormone regulation: biological role and translation into therapy.	Annual review of psychology	2010	55
19631614	1392	Shalev U	Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking.	Brain research	2010	56
19693004	1392	Davis M	Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety.	Neuropsychopharmacology 	2010	321
19726138	1392	Back SE	Reactivity to laboratory stress provocation predicts relapse to cocaine.	Drug and alcohol dependence	2010	47
19906236	1392	Hauger RL	Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.	Annals of the New York Academy of Sciences	2009	70
20160137	1392	Wood SK	Individual differences in reactivity to social stress predict susceptibility and resilience to a depressive phenotype: role of corticotropin-releasing factor.	Endocrinology	2010	68
20377785	1392	Keita AV	The intestinal barrier and its regulation by neuroimmune factors.	Neurogastroenterology and motility 	2010	43
21257974	1392	Stetler C	Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research.	Psychosomatic medicine	2011	116
22488525	1392	Bangasser DA	Sex differences in molecular and cellular substrates of stress.	Cellular and molecular neurobiology	2012	33
22885871	1392	Burkett JP	The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction.	Psychopharmacology	2012	43
24153250	1392	Vanuytsel T	Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism.	Gut	2014	26
24456850	1392	Zorrilla EP	Corticotropin releasing factor: a key role in the neurobiology of addiction.	Frontiers in neuroendocrinology	2014	40
24495607	1392	Belvederi Murri M	HPA axis and aging in depression: systematic review and meta-analysis.	Psychoneuroendocrinology	2014	23
24627581	1392	Mulak A	Sex hormones in the modulation of irritable bowel syndrome.	World journal of gastroenterology	2014	26
25402857	1392	Grieder TE	VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation.	Nature neuroscience	2014	23
25409596	1392	Kwako LE	The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study.	Neuropsychopharmacology 	2015	21
25486982	1392	Gold PW	The organization of the stress system and its dysregulation in depressive illness.	Molecular psychiatry	2015	44
25976297	1392	Mantsch JR	Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress.	Neuropsychopharmacology 	2016	40
8931596	1437	Reiss AL	Brain development, gender and IQ in children. A volumetric imaging study.	Brain 	1996	165
10234034	1437	Gur RC	Sex differences in brain gray and white matter in healthy young adults: correlations with cognitive performance.	The Journal of neuroscience 	1999	134
11811649	1437	Sowell ER	Development of cortical and subcortical brain structures in childhood and adolescence: a structural MRI study.	Developmental medicine and child neurology	2002	170
12952922	1437	Doran KS	Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis.	The Journal of clinical investigation	2003	76
14702257	1437	Ballmaier M	Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRI-based parcellation of the prefrontal cortex.	The American journal of psychiatry	2004	96
16774798	1437	Smith CD	Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly.	Neurobiology of aging	2007	76
17827035	1437	Teipel SJ	Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment.	NeuroImage	2007	59
18761410	1437	Altaye M	Infant brain probability templates for MRI segmentation and normalization.	NeuroImage	2008	51
19157572	1437	Li X	Elevated immune response in the brain of autistic patients.	Journal of neuroimmunology	2009	132
19487648	1437	Driscoll I	Longitudinal pattern of regional brain volume change differentiates normal aging from MCI.	Neurology	2009	118
20030565	1437	Frugier T	In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury.	Journal of neurotrauma	2010	55
20075088	1437	Walhovd KB	Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.	AJNR. American journal of neuroradiology	2010	90
20350607	1437	Sadleir RJ	Transcranial direct current stimulation (tDCS) in a realistic head model.	NeuroImage	2010	48
20484626	1437	Emmanouilidou E	Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival.	The Journal of neuroscience 	2010	237
23365250	1437	Douaud G	Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease.	The Journal of neuroscience 	2013	35
23637915	1437	Matsushita T	Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.	PloS one	2013	26
24643864	1437	Saijo T	Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients.	mBio	2014	30
24667615	1437	Walko TD 3rd	Cerebrospinal fluid mitochondrial DNA: a novel DAMP in pediatric traumatic brain injury.	Shock	2014	20
24691121	1437	Choi SS	Human astrocytes: secretome profiles of cytokines and chemokines.	PloS one	2014	31
25236348	1437	Thrane AS	Drowning stars: reassessing the role of astrocytes in brain edema.	Trends in neurosciences	2014	33
25369488	1437	Hodi FS	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.	JAMA	2014	51
26554728	1437	De Mattos-Arruda L	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.	Nature communications	2015	20
9489700	1641	Gleeson JG	Doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein.	Cell	1998	177
10399933	1641	Gleeson JG	Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons.	Neuron	1999	280
14660786	1641	Jin K	Increased hippocampal neurogenesis in Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	197
15654838	1641	Couillard-Despres S	Doublecortin expression levels in adult brain reflect neurogenesis.	The European journal of neuroscience	2005	210
16387639	1641	Koizumi H	Doublecortin-like kinase functions with doublecortin to mediate fiber tract decussation and neuronal migration.	Neuron	2006	80
16713637	1641	LoTurco JJ	The multipolar stage and disruptions in neuronal migration.	Trends in neurosciences	2006	66
22727374	1641	Bechstedt S	Doublecortin recognizes the 13-protofilament microtubule cooperatively and tracks microtubule ends.	Developmental cell	2012	33
23303060	1641	Anacker C	Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis.	Neuropsychopharmacology 	2013	29
25140959	1641	Jamuar SS	Somatic mutations in cerebral cortical malformations.	The New England journal of medicine	2014	43
15509549	1742	Gylys KH	Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence.	The American journal of pathology	2004	72
15603741	1742	Fukata M	Identification of PSD-95 palmitoylating enzymes.	Neuron	2004	177
16767099	1742	Hahn CG	Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia.	Nature medicine	2006	180
17916412	1742	Glantz LA	Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood.	Neuroscience	2007	56
20921115	1742	Nicodemus KK	Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.	Archives of general psychiatry	2010	40
21490598	1742	Brennand KJ	Modelling schizophrenia using human induced pluripotent stem cells.	Nature	2011	340
21741804	1742	Zohar J	High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: interplay between clinical and animal studies.	European neuropsychopharmacology 	2011	43
22388811	1742	Cook DJ	Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain.	Nature	2012	70
25152434	1742	Hall J	Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity.	Biological psychiatry	2015	52
25392198	1742	Planagumà J	Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice.	Brain 	2015	46
8799184	1813	Laruelle M	Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.	Proceedings of the National Academy of Sciences of the United States of America	1996	204
9429233	1813	Thompson J	D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.	Pharmacogenetics	1997	111
9619147	1813	Abi-Dargham A	Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.	The American journal of psychiatry	1998	130
9672901	1813	Pohjalainen T	The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers.	Molecular psychiatry	1998	140
10395223	1813	Jönsson EG	Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers.	Molecular psychiatry	1999	149
11873706	1813	Seeman P	Atypical antipsychotics: mechanism of action.	Canadian journal of psychiatry. Revue canadienne de psychiatrie	2002	96
14642968	1813	Kapur S	Half a century of antipsychotics and still a central role for dopamine D2 receptors.	Progress in neuro-psychopharmacology and biological psychiatry	2003	99
15992780	1813	Frank GK	Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and 11craclopride.	Biological psychiatry	2005	79
16769933	1813	Pavese N	Microglial activation correlates with severity in Huntington disease: a clinical and PET study.	Neurology	2006	79
18063800	1813	Klein TA	Genetically determined differences in learning from errors.	Science	2007	129
18077373	1813	Zhang Y	Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.	Proceedings of the National Academy of Sciences of the United States of America	2007	123
18097655	1813	Schlagenhauf F	Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.	Psychopharmacology	2008	59
18316420	1813	Fehr C	Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse.	The American journal of psychiatry	2008	60
18829695	1813	Bertolino A	Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia.	Brain 	2009	48
19321766	1813	Jocham G	Dopamine DRD2 polymorphism alters reversal learning and associated neural activity.	The Journal of neuroscience 	2009	56
19620978	1813	Frank MJ	Prefrontal and striatal dopaminergic genes predict individual differences in exploration and exploitation.	Nature neuroscience	2009	118
19902317	1813	Steele KE	Alterations of central dopamine receptors before and after gastric bypass surgery.	Obesity surgery	2010	58
19933774	1813	Marek GJ	Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?	Molecular pharmacology	2010	43
20116437	1813	Stice E	Reward circuitry responsivity to food predicts future increases in body mass: moderating effects of DRD2 and DRD4.	NeuroImage	2010	94
20194823	1813	Kegeles LS	Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.	Archives of general psychiatry	2010	114
20560996	1813	Seeman P	All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.	CNS neuroscience and therapeutics	2011	49
20631684	1813	Frank MJ	Neurogenetics and pharmacology of learning, motivation, and cognition.	Neuropsychopharmacology 	2011	58
20643630	1813	Seeman P	Dopamine D2 receptors as treatment targets in schizophrenia.	Clinical schizophrenia and related psychoses	2010	41
20856250	1813	Volkow ND	Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway.	Molecular psychiatry	2011	59
21150907	1813	Moyer RA	Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse.	Neuropsychopharmacology 	2011	45
21289169	1813	Jocham G	Dopamine-mediated reinforcement learning signals in the striatum and ventromedial prefrontal cortex underlie value-based choices.	The Journal of neuroscience 	2011	56
21349901	1813	O'Sullivan SS	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours.	Brain 	2011	40
21499141	1813	Kim SH	Reduced striatal dopamine D2 receptors in people with Internet addiction.	Neuroreport	2011	41
22474070	1813	Howes OD	The nature of dopamine dysfunction in schizophrenia and what this means for treatment.	Archives of general psychiatry	2012	149
23167711	1813	Boileau I	The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with 11C-(+)-propyl-hexahydro-naphtho-oxazin and 11Craclopride.	Addiction	2013	30
23636255	1813	Fisher BE	Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson's disease.	Neuroreport	2013	25
23650017	1813	Eisenstein SA	A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-(11)Cmethyl)benperidol.	Synapse	2013	26
25890643	1813	Kinon BJ	Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.	Biological psychiatry	2015	20
17601741	1861	Grundmann K	Overexpression of human wildtype torsinA and human DeltaGAG torsinA in a transgenic mouse model causes phenotypic abnormalities.	Neurobiology of disease	2007	55
19641103	1861	Martella G	Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine.	Brain 	2009	48
19826400	1861	Tanabe LM	Primary dystonia: molecules and mechanisms.	Nature reviews. Neurology	2009	51
20482602	1861	Albanese A	EFNS guidelines on diagnosis and treatment of primary dystonias.	European journal of neurology	2011	49
20965251	1861	Niethammer M	Hereditary dystonia as a neurodevelopmental circuit disorder: Evidence from neuroimaging.	Neurobiology of disease	2011	48
24937429	1861	Liang CC	TorsinA hypofunction causes abnormal twisting movements and sensorimotor circuit neurodegeneration.	The Journal of clinical investigation	2014	38
16844713	1917	Asanuma K	Network modulation in the treatment of Parkinson's disease.	Brain 	2006	89
19081516	1917	Benabid AL	Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.	The Lancet. Neurology	2009	159
21825213	1917	Castrioto A	Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation.	Archives of neurology	2011	51
25297382	1917	Jahanshahi M	Parkinson's disease, the subthalamic nucleus, inhibition, and impulsivity.	Movement disorders 	2015	19
10202547	1956	Hatten ME	Central nervous system neuronal migration.	Annual review of neuroscience	1999	158
11283316	1956	Wechsler-Reya R	The developmental biology of brain tumors.	Annual review of neuroscience	2001	101
11431323	1956	Sonoda Y	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.	Cancer research	2001	86
15897449	1956	Howarth M	Targeting quantum dots to surface proteins in living cells with biotin ligase.	Proceedings of the National Academy of Sciences of the United States of America	2005	124
16624948	1956	Almeida CG	Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system.	The Journal of neuroscience 	2006	75
16931954	1956	Hicks DG	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.	The American journal of surgical pathology	2006	68
16962312	1956	Nave KA	Axonal regulation of myelination by neuregulin 1.	Current opinion in neurobiology	2006	122
17483330	1956	Palmieri D	Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.	Cancer research	2007	101
18458038	1956	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	233
19109410	1956	Graner MW	Proteomic and immunologic analyses of brain tumor exosomes.	FASEB journal 	2009	101
19228746	1956	Lin NU	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.	Clinical cancer research 	2009	105
19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
19433789	1956	O'Keeffe GC	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
19544433	1956	Kelly JJ	Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.	Stem cells	2009	62
19596646	1956	Anders CK	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.	Clinical breast cancer	2009	104
19690143	1956	Lu KV	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.	Cancer research	2009	55
20351699	1956	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	57
20647323	1956	Hadjipanayis CG	EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.	Cancer research	2010	82
21030498	1956	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	44
21610077	1956	Kinney SM	Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes.	The Journal of biological chemistry	2011	46
21865399	1956	Grommes C	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.	Neuro-oncology	2011	57
22801742	1956	Doecke JD	Blood-based protein biomarkers for diagnosis of Alzheimer disease.	Archives of neurology	2012	65
22806307	1956	Togashi Y	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.	Cancer chemotherapy and pharmacology	2012	34
22891331	1956	Fenton TR	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.	Proceedings of the National Academy of Sciences of the United States of America	2012	32
23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	80
23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
23964022	1956	Giachino C	Molecular diversity subdivides the adult forebrain neural stem cell population.	Stem cells	2014	24
24105277	1956	Hata A	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.	Cancer	2013	38
24122263	1956	Cummings MC	Metastatic progression of breast cancer: insights from 50 years of autopsies.	The Journal of pathology	2014	25
24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
24310612	1956	Nathanson DA	Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.	Science	2014	70
24390343	1956	Scafidi J	Intranasal epidermal growth factor treatment rescues neonatal brain injury.	Nature	2014	43
25247337	1956	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	25
26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
27959700	1956	Mok TS	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.	The New England journal of medicine	2017	42
10936180	2026	Encinas M	Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells.	Journal of neurochemistry	2000	122
12686268	2026	Nitsche MA	Level of action of cathodal DC polarisation induced inhibition of the human motor cortex.	Clinical neurophysiology 	2003	105
16401847	2026	Zandbergen EG	Prediction of poor outcome within the first 3 days of postanoxic coma.	Neurology	2006	68
22367993	2026	Bouwes A	Prognosis of coma after therapeutic hypothermia: a prospective cohort study.	Annals of neurology	2012	40
24627036	2026	Shahim P	Blood biomarkers for brain injury in concussed professional ice hockey players.	JAMA neurology	2014	45
1464675	2033	Picton TW	The P300 wave of the human event-related potential.	Journal of clinical neurophysiology 	1992	171
2461285	2033	Farwell LA	Talking off the top of your head: toward a mental prosthesis utilizing event-related brain potentials.	Electroencephalography and clinical neurophysiology	1988	249
12829797	2033	Dehaene S	A neuronal network model linking subjective reports and objective physiological data during conscious perception.	Proceedings of the National Academy of Sciences of the United States of America	2003	109
15329307	2033	Bramon E	Meta-analysis of the P300 and P50 waveforms in schizophrenia.	Schizophrenia research	2004	105
19170946	2033	Furdea A	An auditory oddball (P300) spelling system for brain-computer interfaces.	Psychophysiology	2009	53
20478875	2033	Leitman DI	Sensory deficits and distributed hierarchical dysfunction in schizophrenia.	The American journal of psychiatry	2010	41
20869593	2033	Min SW	Acetylation of tau inhibits its degradation and contributes to tauopathy.	Neuron	2010	162
21307242	2033	Jin H	α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity.	The Journal of neuroscience 	2011	38
23994208	2033	De Vos M	Towards a truly mobile auditory brain-computer interface: exploring the P300 to take away.	International journal of psychophysiology 	2014	21
25925534	2033	Twomey DM	The classic P300 encodes a build-to-threshold decision variable.	The European journal of neuroscience	2015	22
12975460	2056	Villa P	Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis.	The Journal of experimental medicine	2003	103
15178821	2056	Wang L	Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats.	Stroke	2004	196
15247477	2056	Leist M	Derivatives of erythropoietin that are tissue protective but not erythropoietic.	Science	2004	157
15928718	2056	Brines M	Emerging biological roles for erythropoietin in the nervous system.	Nature reviews. Neuroscience	2005	97
16634041	2056	Carmichael ST	Cellular and molecular mechanisms of neural repair after stroke: making waves.	Annals of neurology	2006	143
18279854	2056	Theus MH	In vitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain.	Experimental neurology	2008	55
18324962	2056	Arcasoy MO	The non-haematopoietic biological effects of erythropoietin.	British journal of haematology	2008	78
22023617	2056	Shang YC	Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia.	Current neurovascular research	2011	40
22449939	2056	Hruska M	Ephrin regulation of synapse formation, function and plasticity.	Molecular and cellular neurosciences	2012	44
25157725	2056	Leuchter RH	Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age.	JAMA	2014	24
9874150	2247	Svendsen CN	A new method for the rapid and long term growth of human neural precursor cells.	Journal of neuroscience methods	1998	125
11731781	2247	Zhang SC	In vitro differentiation of transplantable neural precursors from human embryonic stem cells.	Nature biotechnology	2001	367
12203386	2247	Ignatova TN	Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro.	Glia	2002	250
19232461	2247	Qiang L	Isolation and characterization of cancer stem like cells in human glioblastoma cell lines.	Cancer letters	2009	55
19439615	2247	Perez JA	A new role for FGF2 as an endogenous inhibitor of anxiety.	The Journal of neuroscience 	2009	48
22272239	2247	Falk A	Capture of neuroepithelial-like stem cells from pluripotent stem cells provides a versatile system for in vitro production of human neurons.	PloS one	2012	52
1710175	2332	Verkerk AJ	Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.	Cell	1991	692
8401578	2332	Devys D	The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation.	Nature genetics	1993	167
11007554	2332	Irwin SA	Dendritic spine structural anomalies in fragile-X mental retardation syndrome.	Cerebral cortex	2000	191
11223852	2332	Irwin SA	Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination.	American journal of medical genetics	2001	206
11445641	2332	Hagerman RJ	Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X.	Neurology	2001	227
11719189	2332	Darnell JC	Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function.	Cell	2001	294
12427636	2332	Brunberg JA	Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction.	AJNR. American journal of neuroradiology	2002	83
14570712	2332	Ceman S	Phosphorylation influences the translation state of FMRP-associated polyribosomes.	Human molecular genetics	2003	108
15805463	2332	Darnell JC	Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes.	Genes and development	2005	97
15861180	2332	Bagni C	From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome.	Nature reviews. Neuroscience	2005	175
16055059	2332	Koekkoek SK	Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome.	Neuron	2005	141
16246864	2332	Iwahashi CK	Protein composition of the intranuclear inclusions of FXTAS.	Brain 	2006	114
17166860	2332	Hessl D	Amygdala dysfunction in men with the fragile X premutation.	Brain 	2007	58
17932962	2332	Gothelf D	Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP).	Annals of neurology	2008	73
18160642	2332	Narayanan U	FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A.	The Journal of neuroscience 	2007	92
18348275	2332	Coffey SM	Expanded clinical phenotype of women with the FMR1 premutation.	American journal of medical genetics. Part A	2008	117
19193898	2332	Christie SB	The FXG: a presynaptic fragile X granule expressed in a subset of developing brain circuits.	The Journal of neuroscience 	2009	68
19422761	2332	Bourgeois JA	A review of fragile X premutation disorders: expanding the psychiatric perspective.	The Journal of clinical psychiatry	2009	79
21651511	2332	Willemsen R	CGG repeat in the FMR1 gene: size matters.	Clinical genetics	2011	41
21783174	2332	Hessl D	Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation.	Biological psychiatry	2011	44
22022567	2332	Sheridan SD	Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.	PloS one	2011	98
22463693	2332	Tassone F	Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS.	Genes, brain, and behavior	2012	41
22887750	2332	Lokanga RA	Somatic expansion in mouse and human carriers of fragile X premutation alleles.	Human mutation	2013	26
22993294	2332	Berry-Kravis EM	Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.	Science translational medicine	2012	99
23042784	2332	Wang T	Genome-wide DNA hydroxymethylation changes are associated with neurodevelopmental genes in the developing human cerebellum.	Human molecular genetics	2012	40
23478018	2332	Sellier C	Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome.	Cell reports	2013	70
23867198	2332	Hagerman R	Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.	The Lancet. Neurology	2013	85
24108107	2332	Yao B	Genome-wide alteration of 5-hydroxymethylcytosine in a mouse model of fragile X-associated tremor/ataxia syndrome.	Human molecular genetics	2014	23
24654675	2332	Doers ME	iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth.	Stem cells and development	2014	23
16341243	2475	Thomas GV	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.	Nature medicine	2006	163
17308353	2475	Jaworski J	The growing role of mTOR in neuronal development and plasticity.	Molecular neurobiology	2006	88
17913600	2475	Swiech L	Role of mTOR in physiology and pathology of the nervous system.	Biochimica et biophysica acta	2008	96
18184959	2475	Bissler JJ	Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.	The New England journal of medicine	2008	278
19234517	2475	Hartman TR	The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.	Oncogene	2009	59
19963289	2475	Hoeffer CA	mTOR signaling: at the crossroads of plasticity, memory and disease.	Trends in neurosciences	2010	270
20615870	2475	Abe N	Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves.	The Journal of biological chemistry	2010	46
21228155	2475	Rieker C	Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling.	The Journal of neuroscience 	2011	39
21269838	2475	Howell JJ	mTOR couples cellular nutrient sensing to organismal metabolic homeostasis.	Trends in endocrinology and metabolism	2011	107
21460795	2475	Galan-Moya EM	Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway.	EMBO reports	2011	38
21890410	2475	Crino PB	mTOR: A pathogenic signaling pathway in developmental brain malformations.	Trends in molecular medicine	2011	51
21907221	2475	Duman RS	Signaling pathways underlying the rapid antidepressant actions of ketamine.	Neuropharmacology	2012	85
22196333	2475	Mazei-Robison MS	Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons.	Neuron	2011	36
22214661	2475	Weber JD	Deconvoluting mTOR biology.	Cell cycle	2012	32
22340590	2475	Pei Y	An animal model of MYC-driven medulloblastoma.	Cancer cell	2012	81
22612226	2475	van Vliet EA	Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation.	Epilepsia	2012	33
22980037	2475	Chong ZZ	Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.	Progress in neurobiology	2012	45
22980985	2475	Lu P	Long-distance growth and connectivity of neural stem cells after severe spinal cord injury.	Cell	2012	127
23265840	2475	Maiese K	mTOR: on target for novel therapeutic strategies in the nervous system.	Trends in molecular medicine	2013	58
23295207	2475	Dwyer JM	Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants.	Biological psychiatry	2013	30
23644232	2475	Wong M	Mammalian target of rapamycin (mTOR) pathways in neurological diseases.	Biomedical journal	2013	29
24249672	2475	Bagatell R	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.	Pediatric blood and cancer	2014	23
24390152	2475	Freret T	Mechanisms underlying the neuroprotective effect of brain reserve against late life depression.	Journal of neural transmission	2015	22
24508508	2475	Li J	Rapamycin: one drug, many effects.	Cell metabolism	2014	66
24585383	2475	Scheffer IE	Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations.	Annals of neurology	2014	27
24666346	2475	Neasta J	mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse.	Journal of neurochemistry	2014	21
24683191	2475	Kato H	Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.	Journal of immunology	2014	22
24727245	2475	Lu Y	Signaling regulations of neuronal regenerative ability.	Current opinion in neurobiology	2014	25
24899720	2475	Caccamo A	Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.	The Journal of neuroscience 	2014	30
25554914	2475	Albert V	mTOR signaling in cellular and organismal energetics.	Current opinion in cell biology	2015	49
25796566	2475	Perluigi M	mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy.	Neurobiology of disease	2015	25
25913192	2475	Venkatesh HS	Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion.	Cell	2015	38
26018084	2475	Nakashima M	Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb.	Annals of neurology	2015	19
26067126	2475	Curatolo P	Neurological and neuropsychiatric aspects of tuberous sclerosis complex.	The Lancet. Neurology	2015	29
27889578	2475	Switon K	Molecular neurobiology of mTOR.	Neuroscience	2017	10
14684836	2571	Veldic M	DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains.	Proceedings of the National Academy of Sciences of the United States of America	2004	80
15237077	2571	Woo TU	Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.	Archives of general psychiatry	2004	109
15700048	2571	Rapoport JL	The neurodevelopmental model of schizophrenia: update 2005.	Molecular psychiatry	2005	201
17726539	2571	Huang HS	GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia.	PloS one	2007	70
19188247	2571	Huang ZJ	Activity-dependent development of inhibitory synapses and innervation pattern: role of GABA signalling and beyond.	The Journal of physiology	2009	50
19321177	2571	Thompson M	Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders.	Journal of psychiatric research	2009	47
21223646	2571	Thompson Ray M	Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders.	Journal of psychiatry and neuroscience 	2011	72
21357831	2571	Boronat A	GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders.	Neurology	2011	38
21419704	2571	LeWitt PA	AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.	The Lancet. Neurology	2011	128
21795557	2571	Hyde TM	Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia.	The Journal of neuroscience 	2011	77
22159125	2571	Volman V	Downregulation of parvalbumin at cortical GABA synapses reduces network gamma oscillatory activity.	The Journal of neuroscience 	2011	47
22948975	2571	Grayson DR	The dynamics of DNA methylation in schizophrenia and related psychiatric disorders.	Neuropsychopharmacology 	2013	60
22983435	2571	Volk DW	Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia.	The American journal of psychiatry	2012	58
24448211	2571	Zhubi A	Increased binding of MeCP2 to the GAD1 and RELN promoters may be mediated by an enrichment of 5-hmC in autism spectrum disorder (ASD) cerebellum.	Translational psychiatry	2014	41
24993056	2571	Glausier JR	Lower glutamic acid decarboxylase 65-kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophrenia.	Biological psychiatry	2015	15
18520330	2596	Haynes RL	Diffuse axonal injury in periventricular leukomalacia as determined by apoptotic marker fractin.	Pediatric research	2008	52
21048117	2596	Zikopoulos B	Changes in prefrontal axons may disrupt the network in autism.	The Journal of neuroscience 	2010	76
24124760	2596	Kingham PJ	Stimulating the neurotrophic and angiogenic properties of human adipose-derived stem cells enhances nerve repair.	Stem cells and development	2014	25
25655556	2596	Dothel G	Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome.	Gastroenterology	2015	20
8493557	2668	Lin LF	GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.	Science	1993	373
12669033	2668	Gill SS	Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.	Nature medicine	2003	186
15739547	2668	Slevin JT	Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.	Journal of neurosurgery	2005	75
16429411	2668	Lang AE	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.	Annals of neurology	2006	162
22328536	2668	Doi D	Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease.	Stem cells	2012	38
9425002	2670	Wolswijk G	Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells.	The Journal of neuroscience 	1998	105
11138011	2670	Brenner M	Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease.	Nature genetics	2001	112
11668683	2670	Zhuo L	hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo.	Genesis	2001	208
12853570	2670	Curtis MA	Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain.	Proceedings of the National Academy of Sciences of the United States of America	2003	116
15280535	2670	Kelly S	Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex.	Proceedings of the National Academy of Sciences of the United States of America	2004	155
15495269	2670	Pekny M	Astrocyte intermediate filaments in CNS pathologies and regeneration.	The Journal of pathology	2004	77
16320258	2670	Quiñones-Hinojosa A	Cellular composition and cytoarchitecture of the adult human subventricular zone: a niche of neural stem cells.	The Journal of comparative neurology	2006	122
16458536	2670	Casper KB	GFAP-positive progenitor cells produce neurons and oligodendrocytes throughout the CNS.	Molecular and cellular neurosciences	2006	64
17405762	2670	Misu T	Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.	Brain 	2007	115
17491094	2670	Thannickal TC	Hypocretin (orexin) cell loss in Parkinson's disease.	Brain 	2007	75
18240313	2670	Lee Y	GFAP promoter elements required for region-specific and astrocyte-specific expression.	Glia	2008	62
18927145	2670	Gouw AA	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology.	Brain 	2008	68
19153578	2670	Chojnacki AK	Identity crisis for adult periventricular neural stem cells: subventricular zone astrocytes, ependymal cells or both?	Nature reviews. Neuroscience	2009	45
19279265	2670	Oberheim NA	Uniquely hominid features of adult human astrocytes.	The Journal of neuroscience 	2009	183
19638961	2670	Lawlor PA	Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.	Molecular therapy 	2009	53
19816235	2670	Ballabh P	Intraventricular hemorrhage in premature infants: mechanism of disease.	Pediatric research	2010	77
20140958	2670	Olabarria M	Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease.	Glia	2010	53
21219963	2670	Middeldorp J	GFAP in health and disease.	Progress in neurobiology	2011	140
21280078	2670	Gunnarsson M	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.	Annals of neurology	2011	41
21702960	2670	Mondello S	Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study.	Critical care	2011	52
21865643	2670	Joseph NM	Enteric glia are multipotent in culture but primarily form glia in the adult rodent gut.	The Journal of clinical investigation	2011	54
23431204	2670	Ponti G	Cell cycle and lineage progression of neural progenitors in the ventricular-subventricular zones of adult mice.	Proceedings of the National Academy of Sciences of the United States of America	2013	47
23469922	2670	Rajkowska G	Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue.	Current drug targets	2013	55
23489259	2670	Okonkwo DO	GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study.	Journal of neurotrauma	2013	30
23579868	2670	Misu T	Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica.	Acta neuropathologica	2013	42
23769173	2670	Yuan T	Human induced pluripotent stem cell-derived neural stem cells survive, migrate, differentiate, and improve neurologic function in a rat model of middle cerebral artery occlusion.	Stem cell research and therapy	2013	25
23865516	2670	Diaz-Arrastia R	Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein.	Journal of neurotrauma	2014	45
24269023	2670	Kamphuis W	Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer's disease.	Neurobiology of aging	2014	20
24332821	2670	Chalak LF	Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy and outcomes in newborns receiving hypothermia therapy.	The Journal of pediatrics	2014	22
24419315	2670	Williams EC	Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons.	Human molecular genetics	2014	38
24501367	2670	Sosunov AA	Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain.	The Journal of neuroscience 	2014	23
24667434	2670	Zhang Z	Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products.	PloS one	2014	24
25034944	2670	Chen C	Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells.	Nature communications	2014	35
11801260	2688	Black PH	Stress, inflammation and cardiovascular disease.	Journal of psychosomatic research	2002	118
12119665	2688	Björntorp P	Do stress reactions cause abdominal obesity and comorbidities?	Obesity reviews 	2001	179
12764120	2688	Benedetti F	Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses.	The Journal of neuroscience 	2003	93
16616726	2688	Munro CA	Sex differences in striatal dopamine release in healthy adults.	Biological psychiatry	2006	81
18256394	2688	Merideth MA	Phenotype and course of Hutchinson-Gilford progeria syndrome.	The New England journal of medicine	2008	138
18279846	2688	Webster Marketon JI	Stress hormones and immune function.	Cellular immunology	2008	60
19703817	2688	Dünser MW	Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress.	Journal of intensive care medicine	2009	56
21464293	2688	Chou SH	Leptin is an effective treatment for hypothalamic amenorrhea.	Proceedings of the National Academy of Sciences of the United States of America	2011	44
21791620	2688	Mantzoros CS	Leptin in human physiology and pathophysiology.	American journal of physiology. Endocrinology and metabolism	2011	88
22607808	2688	Brown P	Iatrogenic Creutzfeldt-Jakob disease, final assessment.	Emerging infectious diseases	2012	48
16373418	2796	Dungan HM	Minireview: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion.	Endocrinology	2006	73
18434521	2796	Zhang C	Kisspeptin depolarizes gonadotropin-releasing hormone neurons through activation of TRPC-like cationic channels.	The Journal of neuroscience 	2008	75
20501670	2796	Lehman MN	Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion.	Endocrinology	2010	130
20529119	2796	Hrabovszky E	The kisspeptin system of the human hypothalamus: sexual dimorphism and relationship with gonadotropin-releasing hormone and neurokinin B neurons.	The European journal of neuroscience	2010	51
20650288	2796	Wierman ME	Gonadotropin-releasing hormone (GnRH) neuron migration: initiation, maintenance and cessation as critical steps to ensure normal reproductive function.	Frontiers in neuroendocrinology	2011	40
17643398	2890	Maeng S	Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.	Biological psychiatry	2008	248
19338055	2890	Lai M	AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location.	Annals of neurology	2009	129
21148011	2890	Schwarz LA	Activity-dependent ubiquitination of GluA1 mediates a distinct AMPA receptor endocytosis and sorting pathway.	The Journal of neuroscience 	2010	57
21338354	2890	Lin A	Nedd4-mediated AMPA receptor ubiquitination regulates receptor turnover and trafficking.	Journal of neurochemistry	2011	47
25369168	2890	Peng X	Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies.	Annals of neurology	2015	22
16862115	2896	Cruts M	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21.	Nature	2006	346
16862116	2896	Baker M	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.	Nature	2006	454
17071926	2896	Mackenzie IR	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene.	Brain 	2006	67
17826340	2896	Rademakers R	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C--&amp;gt;T (Arg493X) mutation: an international initiative.	The Lancet. Neurology	2007	63
18234697	2896	Beck J	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series.	Brain 	2008	57
18245784	2896	Le Ber I	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study.	Brain 	2008	54
18378771	2896	Van Damme P	Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival.	The Journal of cell biology	2008	109
19679189	2896	Rohrer JD	Progressive logopenic/phonological aphasia: erosion of the language network.	NeuroImage	2010	54
20045477	2896	Rohrer JD	Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations.	NeuroImage	2010	43
20489155	2896	Wang WX	miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease.	The American journal of pathology	2010	60
23063362	2896	Almeida S	Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects.	Cell reports	2012	35
12753088	2902	Eugenin EA	MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis.	Journal of neurochemistry	2003	110
15828859	2902	Han K	A combinatorial code for splicing silencing: UAGG and GGGG motifs.	PLoS biology	2005	82
16427029	2902	Rujescu D	A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities.	Biological psychiatry	2006	63
17262855	2902	Dalmau J	Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma.	Annals of neurology	2007	274
17898324	2902	Iizuka T	Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.	Neurology	2008	71
18851928	2902	Dalmau J	Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.	The Lancet. Neurology	2008	361
19020013	2902	Li W	NMDA receptor activation by HIV-Tat protein is clade dependent.	The Journal of neuroscience 	2008	60
22875940	2902	Gleichman AJ	Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain.	The Journal of neuroscience 	2012	42
23070074	2902	Weickert CS	Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia.	Molecular psychiatry	2013	52
24360484	2902	Gresa-Arribas N	Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.	The Lancet. Neurology	2014	71
28095420	2902	Ogden KK	Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology.	PLoS genetics	2017	6
11168837	2908	Welberg LA	Prenatal stress, glucocorticoids and the programming of the brain.	Journal of neuroendocrinology	2001	154
11274650	2908	Pariante CM	Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment.	Biological psychiatry	2001	176
12399952	2908	Webster MJ	Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders.	Molecular psychiatry	2002	80
16214171	2908	de Kloet CS	Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review.	Journal of psychiatric research	2006	80
18536531	2908	Oberlander TF	Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses.	Epigenetics	2008	301
19234457	2908	McGowan PO	Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse.	Nature neuroscience	2009	629
19782477	2908	Alt SR	Differential expression of glucocorticoid receptor transcripts in major depressive disorder is not epigenetically programmed.	Psychoneuroendocrinology	2010	45
20591431	2908	Harris A	Glucocorticoids, prenatal stress and the programming of disease.	Hormones and behavior	2011	147
21980503	2908	Charmandari E	Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man.	PloS one	2011	38
22423117	2908	Krishnadas R	Depression: an inflammatory illness?	Journal of neurology, neurosurgery, and psychiatry	2012	53
22444201	2908	Labonte B	Differential glucocorticoid receptor exon 1(B), 1(C), and 1(H) expression and methylation in suicide completers with a history of childhood abuse.	Biological psychiatry	2012	70
24465557	2908	Na KS	Association between glucocorticoid receptor methylation and hippocampal subfields in major depressive disorder.	PloS one	2014	20
24661442	2908	Yehuda R	Lower methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of veterans with posttraumatic stress disorder.	Biological psychiatry	2015	41
25687413	2908	Turecki G	Effects of the Social Environment and Stress on Glucocorticoid Receptor Gene Methylation: A Systematic Review.	Biological psychiatry	2016	37
26067718	2908	Pivonello R	The Treatment of Cushing's Disease.	Endocrine reviews	2015	18
10973318	3060	Peyron C	A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.	Nature medicine	2000	320
11055430	3060	Thannickal TC	Reduced number of hypocretin neurons in human narcolepsy.	Neuron	2000	317
16247044	3060	Crocker A	Concomitant loss of dynorphin, NARP, and orexin in narcolepsy.	Neurology	2005	70
17468046	3060	McCarley RW	Neurobiology of REM and NREM sleep.	Sleep medicine	2007	103
21034217	3060	Scammell TE	Orexin receptors: pharmacology and therapeutic opportunities.	Annual review of pharmacology and toxicology	2011	56
23135822	3060	Chapman CD	Intranasal treatment of central nervous system dysfunction in humans.	Pharmaceutical research	2013	28
24277819	3060	Sears RM	Orexin/hypocretin system modulates amygdala-dependent threat learning through the locus coeruleus.	Proceedings of the National Academy of Sciences of the United States of America	2013	29
24382351	3060	Hasegawa E	Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.	The Journal of clinical investigation	2014	25
25533960	3060	Yin J	Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.	Nature	2015	22
7748555	3064	DiFiglia M	Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons.	Neuron	1995	133
9267033	3064	Davies SW	Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.	Cell	1997	452
9302293	3064	DiFiglia M	Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.	Science	1997	565
9768849	3064	Jackson GR	Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons.	Neuron	1998	133
10087066	3064	Gutekunst CA	Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.	The Journal of neuroscience 	1999	184
11988536	3064	Dunah AW	Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.	Science	2002	173
12873381	3064	Tang TS	Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1.	Neuron	2003	118
12881722	3064	Zuccato C	Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes.	Nature genetics	2003	216
14978262	3064	Lee WC	Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	95
15340079	3064	Trushina E	Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro.	Molecular and cellular biology	2004	138
16043692	3064	Borovecki F	Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.	Proceedings of the National Academy of Sciences of the United States of America	2005	108
16452635	3064	Benchoua A	Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin.	Molecular biology of the cell	2006	66
16522639	3064	Shibata M	Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1.	The Journal of biological chemistry	2006	133
16893904	3064	Ehrnhoefer DE	Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.	Human molecular genetics	2006	77
16980959	3064	Tam S	The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions.	Nature cell biology	2006	108
17041811	3064	Borrell-Pagès M	Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies.	Cellular and molecular life sciences 	2006	62
17687326	3064	Bennett EJ	Global changes to the ubiquitin system in Huntington's disease.	Nature	2007	175
18488016	3064	Yang SH	Towards a transgenic model of Huntington's disease in a non-human primate.	Nature	2008	108
18550760	3064	Gray M	Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.	The Journal of neuroscience 	2008	183
18625748	3064	Björkqvist M	A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.	The Journal of experimental medicine	2008	126
19076450	3064	Knott AB	Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration.	Annals of the New York Academy of Sciences	2008	63
19460373	3064	Sassone J	Huntington's disease: the current state of research with peripheral tissues.	Experimental neurology	2009	45
19487684	3064	Nekooki-Machida Y	Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity.	Proceedings of the National Academy of Sciences of the United States of America	2009	78
19646924	3064	Tabrizi SJ	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.	The Lancet. Neurology	2009	156
20383138	3064	Martinez-Vicente M	Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease.	Nature neuroscience	2010	180
20923788	3064	Nopoulos PC	Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment.	Brain 	2011	38
21130037	3064	Tabrizi SJ	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.	The Lancet. Neurology	2011	121
21257639	3064	Shirendeb U	Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.	Human molecular genetics	2011	78
21395858	3064	Winner B	Neurodegenerative disease and adult neurogenesis.	The European journal of neuroscience	2011	114
21421997	3064	Gaughwin PM	Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.	Human molecular genetics	2011	50
21971427	3064	Carroll JB	Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.	Molecular therapy 	2011	69
21997870	3064	Shirendeb UP	Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.	Human molecular genetics	2012	60
22031240	3064	McBride JL	Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.	Molecular therapy 	2011	57
22137354	3064	Tabrizi SJ	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.	The Lancet. Neurology	2012	78
22446390	3064	Costa V	Shaping the role of mitochondria in the pathogenesis of Huntington's disease.	The EMBO journal	2012	35
22613578	3064	Juopperi TA	Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.	Molecular brain	2012	62
22709585	3064	Siddiqui A	Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease.	Free radical biology and medicine	2012	32
23160193	3064	Kwan W	Mutant huntingtin impairs immune cell migration in Huntington disease.	The Journal of clinical investigation	2012	33
23664844	3064	Tabrizi SJ	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.	The Lancet. Neurology	2013	98
23963702	3064	Østergaard ME	Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS.	Nucleic acids research	2013	31
24584051	3064	Crotti A	Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.	Nature neuroscience	2014	49
24586208	3064	Hoss AG	MicroRNAs located in the Hox gene clusters are implicated in huntington's disease pathogenesis.	PLoS genetics	2014	22
25017010	3064	Pecho-Vrieseling E	Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons.	Nature neuroscience	2014	26
25437566	3064	Brehme M	A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.	Cell reports	2014	50
17964252	3176	Wandell BA	Visual field maps in human cortex.	Neuron	2007	231
18614670	3176	Boyke J	Training-induced brain structure changes in the elderly.	The Journal of neuroscience 	2008	139
18648501	3176	Driemeyer J	Changes in gray matter induced by learning--revisited.	PloS one	2008	94
20457261	3176	Weiner KS	Sparsely-distributed organization of face and limb activations in human ventral temporal cortex.	NeuroImage	2010	65
10665620	3350	Sargent PA	Brain serotonin1A receptor binding measured by positron emission tomography with 11CWAY-100635: effects of depression and antidepressant treatment.	Archives of general psychiatry	2000	101
12559651	3350	Blier P	Is there a role for 5-HT1A agonists in the treatment of depression?	Biological psychiatry	2003	78
14507979	3350	Lemonde S	Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide.	The Journal of neuroscience 	2003	154
14736842	3350	Neumeister A	Reduced serotonin type 1A receptor binding in panic disorder.	The Journal of neuroscience 	2004	71
17077377	3350	Paterson DS	Multiple serotonergic brainstem abnormalities in sudden infant death syndrome.	JAMA	2006	129
19124686	3350	Fakra E	Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety.	Archives of general psychiatry	2009	61
20592420	3350	Politis M	Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants.	Science translational medicine	2010	55
20614802	3350	Nikolaus S	Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies.	Reviews in the neurosciences	2010	49
24854329	3350	Devinsky O	Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.	Epilepsia	2014	53
15550673	3356	Elphick GF	The human polyomavirus, JCV, uses serotonin receptors to infect cells.	Science	2004	89
18772040	3356	Bubar MJ	Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.	Progress in brain research	2008	52
21550210	3356	Abdolmaleky HM	Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder.	Schizophrenia research	2011	38
25036425	3356	Halberstadt AL	Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.	Behavioural brain research	2015	25
25505168	3356	Howell LL	Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.	Pharmacological reviews	2015	25
19228619	3417	Yan H	IDH1 and IDH2 mutations in gliomas.	The New England journal of medicine	2009	972
19554337	3417	Hartmann C	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.	Acta neuropathologica	2009	219
19737147	3417	Ohgaki H	Genetic alterations and signaling pathways in the evolution of gliomas.	Cancer science	2009	99
19755387	3417	Nobusawa S	IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.	Clinical cancer research 	2009	117
21163902	3417	Christensen BC	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.	Journal of the National Cancer Institute	2011	89
22052461	3417	Jin SG	5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.	Cancer research	2011	110
22270850	3417	Bleeker FE	Recent advances in the molecular understanding of glioblastoma.	Journal of neuro-oncology	2012	36
22281806	3417	Choi C	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.	Nature medicine	2012	130
22343889	3417	Turcan S	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.	Nature	2012	385
22343901	3417	Lu C	IDH mutation impairs histone demethylation and results in a block to cell differentiation.	Nature	2012	379
22415316	3417	Gorovets D	IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.	Clinical cancer research 	2012	40
22829908	3417	Orr BA	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.	PloS one	2012	39
22990979	3417	Zhang W	Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.	Cancer	2013	32
23095825	3417	Weller M	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.	Neuro-oncology	2012	31
26534967	3417	Andronesi OC	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.	Clinical cancer research 	2016	11
27157931	3417	Louis DN	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.	Acta neuropathologica	2016	233
27806376	3417	Tirosh I	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.	Nature	2016	17
8602746	3456	Jacobs LD	Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)	Annals of neurology	1996	255
11006365	3456	Jacobs LD	Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.	The New England journal of medicine	2000	140
16177072	3456	Jack CS	TLR signaling tailors innate immune responses in human microglia and astrocytes.	Journal of immunology	2005	162
16188991	3456	Préhaud C	Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon.	Journal of virology	2005	105
16510745	3456	Rudick RA	Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.	The New England journal of medicine	2006	188
17897326	3456	Venken K	Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.	Immunology	2008	78
19364933	3456	Bielekova B	Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.	Archives of neurology	2009	60
20163990	3456	Wynn D	Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.	The Lancet. Neurology	2010	67
22362918	3456	Soilu-Hänninen M	A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.	Journal of neurology, neurosurgery, and psychiatry	2012	37
24485135	3456	Wingerchuk DM	Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.	Mayo Clinic proceedings	2014	54
25596473	3456	Gharibi T	Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis.	Cellular immunology	2015	16
8787820	3553	Blum-Degen D	Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.	Neuroscience letters	1995	120
9240577	3553	Yoon BH	Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy.	American journal of obstetrics and gynecology	1997	116
10358063	3553	Nath A	Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon.	The Journal of biological chemistry	1999	105
11306611	3553	Tikka T	Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.	The Journal of neuroscience 	2001	192
15777250	3553	Nagatsu T	Inflammatory process in Parkinson's disease: role for cytokines.	Current pharmaceutical design	2005	70
16006665	3553	Fiala M	Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients.	Journal of Alzheimer's disease 	2005	70
19166877	3553	Ren K	Role of interleukin-1beta during pain and inflammation.	Brain research reviews	2009	60
19686799	3553	Long-Smith CM	The influence of microglia on the pathogenesis of Parkinson's disease.	Progress in neurobiology	2009	51
19833175	3553	Lewis SS	Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta.	Neuroscience	2010	43
20127816	3553	Chakraborty S	Inflammasome signaling at the heart of central nervous system pathology.	Journal of neuroscience research	2010	45
21599903	3553	Brochu ME	Developmental regulation of the neuroinflammatory responses to LPS and/or hypoxia-ischemia between preterm and term neonates: An experimental study.	Journal of neuroinflammation	2011	36
21864400	3553	Levesque S	Air pollution &amp;amp; the brain: Subchronic diesel exhaust exposure causes neuroinflammation and elevates early markers of neurodegenerative disease.	Journal of neuroinflammation	2011	45
21906753	3553	Pandey GN	Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims.	Journal of psychiatric research	2012	46
22071871	3553	Zunszain PA	Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis.	Neuropsychopharmacology 	2012	55
22138609	3553	Lukiw WJ	NF-кB-regulated micro RNAs (miRNAs) in primary human brain cells.	Experimental neurology	2012	35
22764097	3553	Denes A	Caspase-1: is IL-1 just the tip of the ICEberg?	Cell death and disease	2012	53
22829270	3553	Librizzi L	Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage.	Annals of neurology	2012	37
23935251	3553	More SV	Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease.	Mediators of inflammation	2013	38
24446952	3553	Rojas A	Cyclooxygenase-2 in epilepsy.	Epilepsia	2014	21
24920309	3553	Jansson D	A role for human brain pericytes in neuroinflammation.	Journal of neuroinflammation	2014	20
24948485	3553	Najjar S	Neuroinflammation and white matter pathology in schizophrenia: systematic review.	Schizophrenia research	2015	33
25043017	3553	Arranz L	Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.	Nature	2014	52
25541493	3553	Black C	Meta-Analysis of Cytokines and Chemokines in Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients.	Biological psychiatry	2015	23
26194183	3553	Fillman SG	Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume.	Molecular psychiatry	2016	18
2044434	3630	DeFronzo RA	Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.	Diabetes care	1991	373
9710447	3630	Barber AJ	Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.	The Journal of clinical investigation	1998	263
12364344	3630	Sorof J	Obesity hypertension in children: a problem of epidemic proportions.	Hypertension	2002	97
12399260	3630	Elliott SS	Fructose, weight gain, and the insulin resistance syndrome.	The American journal of clinical nutrition	2002	170
15288712	3630	Benedict C	Intranasal insulin improves memory in humans.	Psychoneuroendocrinology	2004	106
16250043	3630	Bugianesi E	Insulin resistance: a metabolic pathway to chronic liver disease.	Hepatology	2005	115
16848698	3630	Cahill GF Jr	Fuel metabolism in starvation.	Annual review of nutrition	2006	138
17261637	3630	Gromada J	Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.	Endocrine reviews	2007	149
18230654	3630	Benedict C	Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin.	The Journal of clinical endocrinology and metabolism	2008	53
18525125	3630	Cogswell JP	Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways.	Journal of Alzheimer's disease 	2008	225
20022465	3630	Das UN	Obesity: genes, brain, gut, and environment.	Nutrition	2010	45
20171982	3630	Lambert GW	Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.	Pharmacology and therapeutics	2010	72
21070248	3630	Belgardt BF	CNS leptin and insulin action in the control of energy homeostasis.	Annals of the New York Academy of Sciences	2010	67
21321035	3630	Seifert SM	Health effects of energy drinks on children, adolescents, and young adults.	Pediatrics	2011	100
22500228	3630	Duarte AI	Insulin in central nervous system: more than just a peripheral hormone.	Journal of aging research	2012	44
22745242	3630	Gregg BE	Formation of a human β-cell population within pancreatic islets is set early in life.	The Journal of clinical endocrinology and metabolism	2012	76
22936011	3630	Craft S	Insulin and Alzheimer's disease: untangling the web.	Journal of Alzheimer's disease 	2013	34
23164767	3630	Jacobi J	Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients.	Critical care medicine	2012	64
23485579	3630	De Felice FG	Alzheimer's disease and insulin resistance: translating basic science into clinical applications.	The Journal of clinical investigation	2013	41
23850509	3630	Chen Z	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.	Progress in neurobiology	2013	53
23994581	3630	Rettberg JR	Estrogen: a master regulator of bioenergetic systems in the brain and body.	Frontiers in neuroendocrinology	2014	33
24757202	3630	Chow E	Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk.	Diabetes	2014	33
24931035	3630	Yarchoan M	Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease.	Diabetes	2014	24
24958311	3630	Murray S	Hormonal and neural mechanisms of food reward, eating behaviour and obesity.	Nature reviews. Endocrinology	2014	25
25028522	3630	Heni M	Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men.	Diabetes	2014	23
25043908	3630	Willette AA	Insulin resistance predicts brain amyloid deposition in late middle-aged adults.	Alzheimer's and dementia 	2015	23
25766618	3630	Kim B	Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome.	Experimental and molecular medicine	2015	20
26050667	3630	Betz MJ	Human Brown Adipose Tissue: What We Have Learned So Far.	Diabetes	2015	21
26678809	3630	Jia G	Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.	Nature reviews. Endocrinology	2016	25
8684156	3952	Caro JF	Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance.	Lancet	1996	126
11797013	3952	Minokoshi Y	Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase.	Nature	2002	350
12393845	3952	Farooqi IS	Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency.	The Journal of clinical investigation	2002	281
12727933	3952	Chan JL	The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men.	The Journal of clinical investigation	2003	102
14749507	3952	Myers MG Jr	Leptin receptor signaling and the regulation of mammalian physiology.	Recent progress in hormone research	2004	114
14749508	3952	Bjørbaek C	Leptin signaling in the central nervous system and the periphery.	Recent progress in hormone research	2004	94
15181085	3952	Teff KL	Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women.	The Journal of clinical endocrinology and metabolism	2004	139
16322796	3952	Rosenbaum M	Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight.	The Journal of clinical investigation	2005	137
16445991	3952	Uher R	Cerebral processing of food-related stimuli: effects of fasting and gender.	Behavioural brain research	2006	64
16932309	3952	Brennan AM	Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications.	Nature clinical practice. Endocrinology and metabolism	2006	66
17122358	3952	Farooqi S	Genetics of obesity in humans.	Endocrine reviews	2006	107
17690262	3952	Farooqi IS	Leptin regulates striatal regions and human eating behavior.	Science	2007	137
17986612	3952	Baicy K	Leptin replacement alters brain response to food cues in genetically leptin-deficient adults.	Proceedings of the National Academy of Sciences of the United States of America	2007	66
19166821	3952	Greco SJ	Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells.	Biochemical and biophysical research communications	2009	54
19176740	3952	Blüher S	Leptin in humans: lessons from translational research.	The American journal of clinical nutrition	2009	48
20009056	3952	Lieb W	Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.	JAMA	2009	93
20083828	3952	Kelesidis T	Narrative review: the role of leptin in human physiology: emerging clinical applications.	Annals of internal medicine	2010	78
20600241	3952	Dardeno TA	Leptin in human physiology and therapeutics.	Frontiers in neuroendocrinology	2010	51
21494606	3952	Mueller K	Sex-dependent influences of obesity on cerebral white matter investigated by diffusion-tensor imaging.	PloS one	2011	41
21902800	3952	Carnell S	Neuroimaging and obesity: current knowledge and future directions.	Obesity reviews 	2012	102
23883674	3952	Mark AL	Selective leptin resistance revisited.	American journal of physiology. Regulatory, integrative and comparative physiology	2013	35
25063755	3952	Rosenbaum M	20 years of leptin: role of leptin in energy homeostasis in humans.	The Journal of endocrinology	2014	24
25199978	3952	Park HK	Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism.	Metabolism	2015	35
25232148	3952	Farooqi IS	20 years of leptin: human disorders of leptin action.	The Journal of endocrinology	2014	21
25800063	3952	Allard C	Mendelian randomization supports causality between maternal hyperglycemia and epigenetic regulation of leptin gene in newborns.	Epigenetics	2015	15
12426574	4099	Wong ST	A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein.	Nature neuroscience	2002	85
12931208	4099	Flynn SW	Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins.	Molecular psychiatry	2003	86
17983651	4099	Chew SY	The effect of the alignment of electrospun fibrous scaffolds on Schwann cell maturation.	Biomaterials	2008	56
22133879	4099	Sakai K	Human dental pulp-derived stem cells promote locomotor recovery after complete transection of the rat spinal cord by multiple neuro-regenerative mechanisms.	The Journal of clinical investigation	2012	64
16569698	4128	Meyer-Lindenberg A	Neural mechanisms of genetic risk for impulsivity and violence in humans.	Proceedings of the National Academy of Sciences of the United States of America	2006	163
17088501	4128	Meyer JH	Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression.	Archives of general psychiatry	2006	76
17519928	4128	Buckholtz JW	Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality.	Molecular psychiatry	2008	54
18185497	4128	Yang RJ	Variation in mouse basolateral amygdala volume is associated with differences in stress reactivity and fear learning.	Neuropsychopharmacology 	2008	50
18258310	4128	Buckholtz JW	MAOA and the neurogenetic architecture of human aggression.	Trends in neurosciences	2008	60
18463263	4128	Alia-Klein N	Brain monoamine oxidase A activity predicts trait aggression.	The Journal of neuroscience 	2008	52
2424016	4133	Kosik KS	Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease.	Proceedings of the National Academy of Sciences of the United States of America	1986	267
16549972	4133	Moore DJ	Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment.	AIDS	2006	84
17428465	4133	Yim EK	Synthetic nanostructures inducing differentiation of human mesenchymal stem cells into neuronal lineage.	Experimental cell research	2007	119
22824628	4133	Dash PK	Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.	AIDS	2012	40
1530909	4137	Goedert M	Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms.	Neuron	1992	152
2498079	4137	Goedert M	Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.	The EMBO journal	1989	178
3088567	4137	Grundke-Iqbal I	Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.	Proceedings of the National Academy of Sciences of the United States of America	1986	528
3131773	4137	Goedert M	Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau.	Proceedings of the National Academy of Sciences of the United States of America	1988	165
9836646	4137	Hong M	Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17.	Science	1998	200
10214737	4137	Delacourte A	The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease.	Neurology	1999	117
10391244	4137	Lu PJ	The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.	Nature	1999	160
10595524	4137	Ishihara T	Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform.	Neuron	1999	137
12417659	4137	Allen B	Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.	The Journal of neuroscience 	2002	124
15249677	4137	Liu F	O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	118
15615642	4137	Goedert M	Mutations causing neurodegenerative tauopathies.	Biochimica et biophysica acta	2005	107
15831501	4137	David DC	Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice.	The Journal of biological chemistry	2005	79
16443603	4137	Cripps D	Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation.	The Journal of biological chemistry	2006	67
16807328	4137	Dickey CA	Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species.	The Journal of neuroscience 	2006	78
17159101	4137	Arvanitakis Z	Diabetes is related to cerebral infarction but not to AD pathology in older persons.	Neurology	2006	88
21304998	4137	Whittington RA	Propofol directly increases tau phosphorylation.	PloS one	2011	42
21427723	4137	Cohen TJ	The acetylation of tau inhibits its function and promotes pathological tau aggregation.	Nature communications	2011	96
22608668	4137	Grossman M	The non-fluent/agrammatic variant of primary progressive aphasia.	The Lancet. Neurology	2012	31
22668776	4137	Chai X	Constitutive secretion of tau protein by an unconventional mechanism.	Neurobiology of disease	2012	36
22723018	4137	Trabzuni D	MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies.	Human molecular genetics	2012	46
23109154	4137	Bennett DA	Relation of neuropathology to cognition in persons without cognitive impairment.	Annals of neurology	2012	54
23234879	4137	Chien DT	Early clinical PET imaging results with the novel PHF-tau radioligand F-18-T807.	Journal of Alzheimer's disease 	2013	123
23411393	4137	Xia CF	(18)FT807, a novel tau positron emission tomography imaging agent for Alzheimer's disease.	Alzheimer's and dementia 	2013	89
23684085	4137	Spillantini MG	Tau pathology and neurodegeneration.	The Lancet. Neurology	2013	121
23948934	4137	Chien DT	Early clinical PET imaging results with the novel PHF-tau radioligand F18-T808.	Journal of Alzheimer's disease 	2014	45
25393609	4137	Sokolow S	Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.	Journal of neurochemistry	2015	19
25921538	4137	Moore S	APP metabolism regulates tau proteostasis in human cerebral cortex neurons.	Cell reports	2015	23
27357347	4137	Smith R	18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.	Brain 	2016	15
10049950	4155	Kerschensteiner M	Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?	The Journal of experimental medicine	1999	133
12853586	4155	Berger T	Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.	The New England journal of medicine	2003	76
16079912	4155	Li Y	Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule.	The EMBO journal	2005	74
17000961	4155	Wegner C	Neocortical neuronal, synaptic, and glial loss in multiple sclerosis.	Neurology	2006	66
19642704	4155	Harauz G	Structural polymorphism and multifunctionality of myelin basic protein.	Biochemistry	2009	47
20526343	4155	Ji Q	Viral infection triggers central nervous system autoimmunity via activation of CD8+ T cells expressing dual TCRs.	Nature immunology	2010	50
20625086	4155	Pitt D	Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging.	Archives of neurology	2010	52
22102821	4155	Girirajan S	Relative burden of large CNVs on a range of neurodevelopmental phenotypes.	PLoS genetics	2011	96
23378219	4155	Philips T	Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis.	Brain 	2013	38
23740901	4155	Lutterotti A	Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.	Science translational medicine	2013	63
16225830	4204	Armstrong DD	Neuropathology of Rett syndrome.	Journal of child neurology	2005	76
19442733	4204	Chapleau CA	Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.	Neurobiology of disease	2009	71
19717458	4204	Joyner AH	A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
19833297	4204	Urdinguio RG	Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies.	The Lancet. Neurology	2009	148
20425298	4204	Gonzales ML	The role of MeCP2 in brain development and neurodevelopmental disorders.	Current psychiatry reports	2010	48
21085180	4204	Muotri AR	L1 retrotransposition in neurons is modulated by MeCP2.	Nature	2010	178
21372149	4204	Cheung AY	Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation.	Human molecular genetics	2011	94
21807996	4204	Kim KY	Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2011	71
22037496	4204	Szulwach KE	5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging.	Nature neuroscience	2011	225
23431031	4204	Han K	Human-specific regulation of MeCP2 levels in fetal brains by microRNA miR-483-5p.	Genes and development	2013	31
24094325	4204	Li Y	Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons.	Cell stem cell	2013	81
25644311	4204	Djuric U	MECP2e1 isoform mutation affects the form and function of neurons derived from Rett syndrome patient iPS cells.	Neurobiology of disease	2015	18
25650246	4204	Spiers H	Methylomic trajectories across human fetal brain development.	Genome research	2015	43
25739960	4204	Kinde B	Reading the unique DNA methylation landscape of the brain: Non-CpG methylation, hydroxymethylation, and MeCP2.	Proceedings of the National Academy of Sciences of the United States of America	2015	37
26733678	4204	Tang X	KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2016	10
17387725	4763	Listernick R	Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.	Annals of neurology	2007	64
19111880	4763	Alcantara Llaguno S	Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.	Cancer cell	2009	197
20027112	4763	Jett K	Clinical and genetic aspects of neurofibromatosis 1.	Genetics in medicine 	2010	59
20821343	4763	Wiemels J	Epidemiology and etiology of meningioma.	Journal of neuro-oncology	2010	83
8379998	4771	Rouleau GA	Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.	Nature	1993	221
8453669	4771	Trofatter JA	A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.	Cell	1993	200
19476995	4771	Asthagiri AR	Neurofibromatosis type 2.	Lancet	2009	56
24261697	4771	Goutagny S	High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.	Brain pathology	2014	22
25893302	4771	Petrilli AM	Role of Merlin/NF2 inactivation in tumor biology.	Oncogene	2016	13
10097000	4803	Berkley KJ	Sex differences in pain.	The Behavioral and brain sciences	1997	115
11040419	4803	Murer MG	Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease.	Progress in neurobiology	2001	144
15852017	4803	Tuszynski MH	A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.	Nature medicine	2005	179
16336965	4803	Crigler L	Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis.	Experimental neurology	2006	118
23190582	4803	Aloe L	Nerve growth factor: from the early discoveries to the potential clinical use.	Journal of translational medicine	2012	53
26302439	4803	Tuszynski MH	Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.	JAMA neurology	2015	23
18385673	4852	Zhou Z	Genetic variation in human NPY expression affects stress response and emotion.	Nature	2008	114
20308990	4852	Lesch KP	Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree.	Molecular psychiatry	2011	37
23040809	4852	van den Pol AN	Neuropeptide transmission in brain circuits.	Neuron	2012	90
9513736	5020	Modahl C	Plasma oxytocin levels in autistic children.	Biological psychiatry	1998	133
10941275	5020	Taylor SE	Biobehavioral responses to stress in females: tend-and-befriend, not fight-or-flight.	Psychological review	2000	291
11587772	5020	Porges SW	The polyvagal theory: phylogenetic substrates of a social nervous system.	International journal of psychophysiology 	2001	145
16890230	5020	Lim MM	Neuropeptidergic regulation of affiliative behavior and social bonding in animals.	Hormones and behavior	2006	133
17137561	5020	Domes G	Oxytocin improves "mind-reading" in humans.	Biological psychiatry	2007	218
18498743	5020	Baumgartner T	Oxytocin shapes the neural circuitry of trust and trust adaptation in humans.	Neuron	2008	219
18579733	5020	Petrovic P	Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity.	The Journal of neuroscience 	2008	111
18988842	5020	Donaldson ZR	Oxytocin, vasopressin, and the neurogenetics of sociality.	Science	2008	295
19553027	5020	Grippo AJ	Oxytocin protects against negative behavioral and autonomic consequences of long-term social isolation.	Psychoneuroendocrinology	2009	58
19710635	5020	Strathearn L	Adult attachment predicts maternal brain and oxytocin response to infant cues.	Neuropsychopharmacology 	2009	126
20047458	5020	Macdonald K	The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans.	Harvard review of psychiatry	2010	78
20371820	5020	Hurlemann R	Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans.	The Journal of neuroscience 	2010	120
20421469	5020	Gamer M	Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans.	Proceedings of the National Academy of Sciences of the United States of America	2010	105
20557568	5020	Baskerville TA	Dopamine and oxytocin interactions underlying behaviors: potential contributions to behavioral disorders.	CNS neuroscience and therapeutics	2010	48
20720535	5020	Labuschagne I	Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder.	Neuropsychopharmacology 	2010	106
21470595	5020	Riem MM	Oxytocin modulates amygdala, insula, and inferior frontal gyrus responses to infant crying: a randomized controlled trial.	Biological psychiatry	2011	80
21696997	5020	Bartz JA	Social effects of oxytocin in humans: context and person matter.	Trends in cognitive sciences	2011	252
21852800	5020	Meyer-Lindenberg A	Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine.	Nature reviews. Neuroscience	2011	278
21881566	5020	Atzil S	Specifying the neurobiological basis of human attachment: brain, hormones, and behavior in synchronous and intrusive mothers.	Neuropsychopharmacology 	2011	50
22100184	5020	Bosch OJ	Both oxytocin and vasopressin are mediators of maternal care and aggression in rodents: from central release to sites of action.	Hormones and behavior	2012	62
22189289	5020	Riem MM	No laughing matter: intranasal oxytocin administration changes functional brain connectivity during exposure to infant laughter.	Neuropsychopharmacology 	2012	39
22265852	5020	Guastella AJ	A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions.	Hormones and behavior	2012	76
22365820	5020	Lischke A	Oxytocin increases amygdala reactivity to threatening scenes in females.	Psychoneuroendocrinology	2012	43
22795645	5020	Weisman O	Oxytocin administration to parent enhances infant physiological and behavioral readiness for social engagement.	Biological psychiatry	2012	39
22981649	5020	Lukas M	Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders.	Behavioural brain research	2013	26
23055480	5020	Yamasue H	Integrative approaches utilizing oxytocin to enhance prosocial behavior: from animal and human social behavior to autistic social dysfunction.	The Journal of neuroscience 	2012	33
23159011	5020	Bethlehem RA	Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies.	Psychoneuroendocrinology	2013	46
23419544	5020	Groppe SE	Oxytocin influences processing of socially relevant cues in the ventral tegmental area of the human brain.	Biological psychiatry	2013	36
23510581	5020	Domes G	Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder.	Biological psychiatry	2013	43
24050183	5020	Carter CS	Oxytocin pathways and the evolution of human behavior.	Annual review of psychology	2014	60
24277856	5020	Scheele D	Oxytocin enhances brain reward system responses in men viewing the face of their female partner.	Proceedings of the National Academy of Sciences of the United States of America	2013	38
24297883	5020	Gordon I	Oxytocin enhances brain function in children with autism.	Proceedings of the National Academy of Sciences of the United States of America	2013	63
24594871	5020	Dodhia S	Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder.	Neuropsychopharmacology 	2014	27
24694924	5020	Scheele D	An oxytocin-induced facilitation of neural and emotional responses to social touch correlates inversely with autism traits.	Neuropsychopharmacology 	2014	27
25349162	5020	Carson DS	Cerebrospinal fluid and plasma oxytocin concentrations are positively correlated and negatively predict anxiety in children.	Molecular psychiatry	2015	23
25542304	5020	Eckstein M	Oxytocin facilitates the extinction of conditioned fear in humans.	Biological psychiatry	2015	20
26001309	5020	Grinevich V	Assembling the Puzzle: Pathways of Oxytocin Signaling in the Brain.	Biological psychiatry	2016	13
26210057	5020	Walum H	Statistical and Methodological Considerations for the Interpretation of Intranasal Oxytocin Studies.	Biological psychiatry	2016	25
26321019	5020	Shamay-Tsoory SG	The Social Salience Hypothesis of Oxytocin.	Biological psychiatry	2016	23
9737281	5362	Tsai TF	West Nile encephalitis epidemic in southeastern Romania.	Lancet	1998	142
20920824	5362	Mwanza JC	Ability of cirrus HD-OCT optic nerve head parameters to discriminate normal from glaucomatous eyes.	Ophthalmology	2011	49
22418228	5362	Jia Y	Split-spectrum amplitude-decorrelation angiography with optical coherence tomography.	Optics express	2012	186
24845642	5362	Wilk MA	Relationship between foveal cone specialization and pit morphology in albinism.	Investigative ophthalmology and visual science	2014	24
26255817	5362	Wang X	Correlation between optic disc perfusion and glaucomatous severity in patients with open-angle glaucoma: an optical coherence tomography angiography study.	Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie	2015	33
11502812	5443	Vgontzas AN	Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications.	The Journal of clinical endocrinology and metabolism	2001	108
12764219	5443	Schommer NC	Dissociation between reactivity of the hypothalamus-pituitary-adrenal axis and the sympathetic-adrenal-medullary system to repeated psychosocial stress.	Psychosomatic medicine	2003	76
15039002	5443	Barr CS	Rearing condition and rh5-HTTLPR interact to influence limbic-hypothalamic-pituitary-adrenal axis response to stress in infant macaques.	Biological psychiatry	2004	111
15135942	5443	Han JS	Acupuncture and endorphins.	Neuroscience letters	2004	106
15159175	5443	Oswald LM	Opioids and alcoholism.	Physiology and behavior	2004	76
17408865	5443	Wilhelm I	Is the cortisol awakening rise a response to awakening?	Psychoneuroendocrinology	2007	64
20026350	5443	Clow A	The cortisol awakening response: more than a measure of HPA axis function.	Neuroscience and biobehavioral reviews	2010	68
20348094	5443	Hall JE	Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins.	The Journal of biological chemistry	2010	118
21955155	5443	Bazov I	The endogenous opioid system in human alcoholics: molecular adaptations in brain areas involved in cognitive control of addiction.	Addiction biology	2013	30
23426689	5443	Zhan C	Acute and long-term suppression of feeding behavior by POMC neurons in the brainstem and hypothalamus, respectively.	The Journal of neuroscience 	2013	61
26004339	5443	Lacroix A	Cushing's syndrome.	Lancet	2015	32
8598754	5621	Will RG	A new variant of Creutzfeldt-Jakob disease in the UK.	Lancet	1996	314
8651649	5621	Parchi P	Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease.	Annals of neurology	1996	136
10443888	5621	Parchi P	Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects.	Annals of neurology	1999	211
10766242	5621	Matsunami H	A family of candidate taste receptors in human and mouse.	Nature	2000	119
14522861	5621	Gambetti P	Sporadic and familial CJD: classification and characterisation.	British medical bulletin	2003	118
15741275	5621	Safar JG	Diagnosis of human prion disease.	Proceedings of the National Academy of Sciences of the United States of America	2005	81
16135751	5621	Kong Q	Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models.	The Journal of neuroscience 	2005	78
16297838	5621	Polymenidou M	Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease.	The Lancet. Neurology	2005	69
16391566	5621	Mead S	Prion disease genetics.	European journal of human genetics 	2006	63
16518470	5621	Nonno R	Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles.	PLoS pathogens	2006	62
17161728	5621	Wroe SJ	Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report.	Lancet	2006	86
17585315	5621	Aguzzi A	Insights into prion strains and neurotoxicity.	Nature reviews. Molecular cell biology	2007	98
17923484	5621	Barron RM	High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo.	The Journal of biological chemistry	2007	69
18096717	5621	Colby DW	Prion detection by an amyloid seeding assay.	Proceedings of the National Academy of Sciences of the United States of America	2007	67
18558863	5621	Aguzzi A	The prion's elusive reason for being.	Annual review of neuroscience	2008	132
18571782	5621	Gambetti P	A novel human disease with abnormal prion protein sensitive to protease.	Annals of neurology	2008	76
19231987	5621	Caughey B	Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.	Annual review of biochemistry	2009	119
19424437	5621	Marijanovic Z	Identification of an intracellular site of prion conversion.	PLoS pathogens	2009	64
19436715	5621	Barria MA	De novo generation of infectious prions in vitro produces a new disease phenotype.	PLoS pathogens	2009	50
19789378	5621	Aguzzi A	Prions: protein aggregation and infectious diseases.	Physiological reviews	2009	118
20070383	5621	Peden A	Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia.	Haemophilia 	2010	41
20547859	5621	Bishop MT	Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
21278748	5621	Atarashi R	Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion.	Nature medicine	2011	93
21654636	5621	Freir DB	Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites.	Nature communications	2011	87
24336048	5621	Joshi P	Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles.	Cell death and differentiation	2014	31
25099576	5621	Orrú CD	A test for Creutzfeldt-Jakob disease using nasal brushings.	The New England journal of medicine	2014	39
26324905	5621	Prusiner SB	Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism.	Proceedings of the National Academy of Sciences of the United States of America	2015	63
8755489	5663	Thinakaran G	Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo.	Neuron	1996	206
10206645	5663	De Strooper B	A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain.	Nature	1999	466
16203860	5663	Yu WH	Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease.	The Journal of cell biology	2005	226
16752394	5663	Kumar-Singh S	Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.	Human mutation	2006	89
17079810	5663	Mosconi L	Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease.	Journal of nuclear medicine 	2006	72
17553989	5663	Klunk WE	Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.	The Journal of neuroscience 	2007	111
17962197	5663	Page RM	Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation.	The Journal of biological chemistry	2008	53
20616000	5663	Miller JA	Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways.	Proceedings of the National Academy of Sciences of the United States of America	2010	124
21816272	5663	Qiang L	Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons.	Cell	2011	107
21900357	5663	Yagi T	Modeling familial Alzheimer's disease with induced pluripotent stem cells.	Human molecular genetics	2011	120
23137948	5663	Reiman EM	Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.	The Lancet. Neurology	2012	98
23761040	5663	Potter R	Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers.	Science translational medicine	2013	42
23773064	5663	Wolfe DM	Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification.	The European journal of neuroscience	2013	53
23884042	5663	Chhatwal JP	Impaired default network functional connectivity in autosomal dominant Alzheimer disease.	Neurology	2013	32
25307057	5663	Choi SH	A three-dimensional human neural cell culture model of Alzheimer's disease.	Nature	2014	111
26481686	5663	Szaruga M	Qualitative changes in human γ-secretase underlie familial Alzheimer's disease.	The Journal of experimental medicine	2015	16
10639397	5775	Halgren E	Cognitive response profile of the human fusiform face area as determined by MEG.	Cerebral cortex	2000	94
11209067	5775	Gross J	Dynamic imaging of coherent sources: Studying neural interactions in the human brain.	Proceedings of the National Academy of Sciences of the United States of America	2001	245
15979027	5775	Apkarian AV	Human brain mechanisms of pain perception and regulation in health and disease.	European journal of pain	2005	484
16814448	5775	Pulvermüller F	Language outside the focus of attention: the mismatch negativity as a tool for studying higher cognitive processes.	Progress in neurobiology	2006	71
16859985	5775	Bartolomei F	Disturbed functional connectivity in brain tumour patients: evaluation by graph analysis of synchronization matrices.	Clinical neurophysiology 	2006	61
16950225	5775	Wilson TW	Children and adolescents with autism exhibit reduced MEG steady-state gamma responses.	Biological psychiatry	2007	97
17234696	5775	Birbaumer N	Brain-computer interfaces: communication and restoration of movement in paralysis.	The Journal of physiology	2007	94
17266107	5775	Stam CJ	Phase lag index: assessment of functional connectivity from multi channel EEG and MEG with diminished bias from common sources.	Human brain mapping	2007	185
17274021	5775	Lachaux JP	Relationship between task-related gamma oscillations and BOLD signal: new insights from combined fMRI and intracranial EEG.	Human brain mapping	2007	86
17698205	5775	Srinivasan R	EEG and MEG coherence: measures of functional connectivity at distinct spatial scales of neocortical dynamics.	Journal of neuroscience methods	2007	75
19098986	5775	Osipova D	Gamma power is phase-locked to posterior alpha activity.	PloS one	2008	87
19343801	5775	Jerbi K	Task-related gamma-band dynamics from an intracerebral perspective: review and implications for surface EEG and MEG.	Human brain mapping	2009	65
19664815	5775	Pulvermüller F	Understanding in an instant: neurophysiological evidence for mechanistic language circuits in the brain.	Brain and language	2009	48
19932756	5775	Palva S	Graph properties of synchronized cortical networks during visual working memory maintenance.	NeuroImage	2010	54
20607220	5775	Iannetti GD	From the neuromatrix to the pain matrix (and back).	Experimental brain research	2010	77
21215806	5775	Gaetz W	Relating MEG measured motor cortical oscillations to resting γ-aminobutyric acid (GABA) concentration.	NeuroImage	2011	52
21697363	5775	Todorovic A	Prior expectation mediates neural adaptation to repeated sounds in the auditory cortex: an MEG study.	The Journal of neuroscience 	2011	62
21723129	5775	Thut G	Rhythmic TMS causes local entrainment of natural oscillatory signatures.	Current biology 	2011	77
22723684	5775	Sohoglu E	Predictive top-down integration of prior knowledge during speech perception.	The Journal of neuroscience 	2012	57
22750156	5775	Lachaux JP	High-frequency neural activity and human cognition: past, present and possible future of intracranial EEG research.	Progress in neurobiology	2012	65
22815496	5775	Poil SS	Critical-state dynamics of avalanches and oscillations jointly emerge from balanced excitation/inhibition in neuronal networks.	The Journal of neuroscience 	2012	41
23380166	5775	Charles L	Distinct brain mechanisms for conscious versus subliminal error detection.	NeuroImage	2013	32
23536086	5775	Ding N	Adaptive temporal encoding leads to a background-insensitive cortical representation of speech.	The Journal of neuroscience 	2013	32
24198372	5775	Roux F	The phase of thalamic alpha activity modulates cortical gamma-band activity: evidence from resting-state MEG recordings.	The Journal of neuroscience 	2013	26
25727740	5775	Tsvetanov KA	The effect of ageing on fMRI: Correction for the confounding effects of vascular reactivity evaluated by joint fMRI and MEG in 335 adults.	Human brain mapping	2015	24
27009409	5775	Coffey EB	Cortical contributions to the auditory frequency-following response revealed by MEG.	Nature communications	2016	17
11955958	5816	Zhang ZJ	A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia.	Schizophrenia research	2002	92
19941350	5816	Kataoka Y	Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome.	The Journal of comparative neurology	2010	99
21041246	5816	Fung SJ	Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia.	The American journal of psychiatry	2010	123
24217255	5816	Glausier JR	Altered parvalbumin basket cell inputs in the dorsolateral prefrontal cortex of schizophrenia subjects.	Molecular psychiatry	2014	35
24650500	5816	Lewis DA	Inhibitory neurons in human cortical circuits: substrate for cognitive dysfunction in schizophrenia.	Current opinion in neurobiology	2014	36
25043046	5816	Xue M	Equalizing excitation-inhibition ratios across visual cortical neurons.	Nature	2014	78
25561540	5816	Xu M	Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
25863358	5816	Gonzalez-Burgos G	Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia.	Biological psychiatry	2015	41
26830140	5816	Canetta S	Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons.	Molecular psychiatry	2016	12
2137202	6010	Dryja TP	A point mutation of the rhodopsin gene in one form of retinitis pigmentosa.	Nature	1990	212
2937147	6010	Nathans J	Molecular genetics of human color vision: the genes encoding blue, green, and red pigments.	Science	1986	225
11724467	6010	Salem N Jr	Mechanisms of action of docosahexaenoic acid in the nervous system.	Lipids	2001	161
12634111	6010	Gupta N	Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration.	Experimental eye research	2003	135
12866125	6010	Jones BW	Retinal remodeling triggered by photoreceptor degenerations.	The Journal of comparative neurology	2003	118
15177205	6010	Lamb TD	Dark adaptation and the retinoid cycle of vision.	Progress in retinal and eye research	2004	180
17591900	6010	Duncan JL	High-resolution imaging with adaptive optics in patients with inherited retinal degeneration.	Investigative ophthalmology and visual science	2007	99
17693260	6010	Chuang JZ	SARA-regulated vesicular targeting underlies formation of the light-sensing organelle in mammalian rods.	Cell	2007	72
22074921	6010	Palczewski K	Chemistry and biology of vision.	The Journal of biological chemistry	2012	76
23139242	6010	Singh R	iPS cell modeling of Best disease: insights into the pathophysiology of an inherited macular degeneration.	Human molecular genetics	2013	68
24135424	6010	Wang J	Molecular complexes that direct rhodopsin transport to primary cilia.	Progress in retinal and eye research	2014	38
12645009	6285	Rothermundt M	S100B in brain damage and neurodegeneration.	Microscopy research and technique	2003	79
17319915	6285	Marchi N	Seizure-promoting effect of blood-brain barrier disruption.	Epilepsia	2007	115
19705461	6285	Mori T	Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.	Glia	2010	50
23783559	6285	Niranjan R	The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes.	Molecular neurobiology	2014	24
1734300	6531	Jack CR Jr	MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease.	Neurology	1992	132
3399080	6531	McGeer PL	Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains.	Neurology	1988	417
9126740	6531	Volkow ND	Relationship between subjective effects of cocaine and dopamine transporter occupancy.	Nature	1997	130
9417971	6531	Gunn RN	Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.	NeuroImage	1997	167
9537821	6531	Tatsumi M	Pharmacological profile of antidepressants and related compounds at human monoamine transporters.	European journal of pharmacology	1997	121
9763484	6531	McCann UD	Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with 11CWIN-35,428.	The Journal of neuroscience 	1998	123
9766762	6531	Volkow ND	Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.	The American journal of psychiatry	1998	112
10649826	6531	Heinz A	Genotype influences in vivo dopamine transporter availability in human striatum.	Neuropsychopharmacology 	2000	116
11160455	6531	Volkow ND	Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.	The Journal of neuroscience 	2001	104
11292651	6531	Lee FJ	Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.	FASEB journal 	2001	88
14608034	6531	Lustig C	Functional deactivations: change with age and dementia of the Alzheimer type.	Proceedings of the National Academy of Sciences of the United States of America	2003	235
15293269	6531	Ponsen MM	Idiopathic hyposmia as a preclinical sign of Parkinson's disease.	Annals of neurology	2004	90
15590952	6531	Fahn S	Levodopa and the progression of Parkinson's disease.	The New England journal of medicine	2004	180
15872345	6531	van Dyck CH	Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene.	Journal of nuclear medicine 	2005	80
16192352	6531	Rueda MR	Training, maturation, and genetic influences on the development of executive attention.	Proceedings of the National Academy of Sciences of the United States of America	2005	154
16518646	6531	Johanson CE	Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers.	Psychopharmacology	2006	65
17267664	6531	Bolan EA	D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism.	Molecular pharmacology	2007	63
17470495	6531	Huang C	Changes in network activity with the progression of Parkinson's disease.	Brain 	2007	87
17493050	6531	Chang L	Structural and metabolic brain changes in the striatum associated with methamphetamine abuse.	Addiction	2007	132
17586681	6531	Redmond DE Jr	Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	100
17825265	6531	Howell LL	Monoamine transporters and psychostimulant addiction.	Biochemical pharmacology	2008	55
17992686	6531	McCann UD	Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users.	Synapse	2008	70
18579413	6531	Chang L	Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse.	NeuroImage	2008	55
18617632	6531	Binda F	Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux.	Molecular pharmacology	2008	53
19006193	6531	Kordower JH	Transplanted dopaminergic neurons develop PD pathologic changes: a second case report.	Movement disorders 	2008	68
19091889	6531	van de Giessen E	Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3.	Journal of nuclear medicine 	2009	48
19293415	6531	Volkow ND	Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications.	JAMA	2009	127
19738093	6531	Volkow ND	Evaluating dopamine reward pathway in ADHD: clinical implications.	JAMA	2009	129
20048223	6531	Nakamura K	Brain serotonin and dopamine transporter bindings in adults with high-functioning autism.	Archives of general psychiatry	2010	68
20497720	6531	Xie HR	SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease.	Chinese medical journal	2010	71
20846908	6531	Iranzo A	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study corrected.	The Lancet. Neurology	2010	47
21717292	6531	Purohit V	Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.	Molecular neurobiology	2011	48
22315428	6531	Lundblad M	Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.	Proceedings of the National Academy of Sciences of the United States of America	2012	59
23065479	6531	Dale RC	Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders.	Brain 	2012	43
23170765	6531	Cameron KN	Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter.	British journal of pharmacology	2013	32
23371489	6531	Cameron K	Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce opposite effects at the human dopamine transporter.	Psychopharmacology	2013	29
23562390	6531	Iranzo A	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study.	The Lancet. Neurology	2013	52
24102293	6531	Calipari ES	Extended access of cocaine self-administration results in tolerance to the dopamine-elevating and locomotor-stimulating effects of cocaine.	Journal of neurochemistry	2014	21
24911152	6531	Hansen FH	Missense dopamine transporter mutations associate with adult parkinsonism and ADHD.	The Journal of clinical investigation	2014	21
26171719	6531	Hryhorczuk C	Dampened Mesolimbic Dopamine Function and Signaling by Saturated but not Monounsaturated Dietary Lipids.	Neuropsychopharmacology 	2016	13
11803458	6532	Bennett AJ	Early experience and serotonin transporter gene variation interact to influence primate CNS function.	Molecular psychiatry	2002	135
12130784	6532	Hariri AR	Serotonin transporter genetic variation and the response of the human amygdala.	Science	2002	485
12973026	6532	Ichise M	Linearized reference tissue parametric imaging methods: application to 11CDASB positron emission tomography studies of the serotonin transporter in human brain.	Journal of cerebral blood flow and metabolism 	2003	143
15592465	6532	Heinz A	Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter.	Nature neuroscience	2005	164
15699291	6532	Hariri AR	A susceptibility gene for affective disorders and the response of the human amygdala.	Archives of general psychiatry	2005	217
15880108	6532	Pezawas L	5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression.	Nature neuroscience	2005	483
16012532	6532	Maciag D	Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry.	Neuropsychopharmacology 	2006	70
16389202	6532	Sekine Y	Brain serotonin transporter density and aggression in abstinent methamphetamine abusers.	Archives of general psychiatry	2006	76
16390888	6532	Parsey RV	Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain.	The American journal of psychiatry	2006	73
16442081	6532	Hariri AR	Imaging genetics: perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing.	Biological psychiatry	2006	101
16530463	6532	Hariri AR	Genetics of emotional regulation: the role of the serotonin transporter in neural function.	Trends in cognitive sciences	2006	195
17406646	6532	Dannlowski U	5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression.	Neuropsychopharmacology 	2008	51
17956909	6532	Kish SJ	Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.	Brain 	2008	67
18005940	6532	Gotlib IH	HPA axis reactivity: a mechanism underlying the associations among 5-HTTLPR, stress, and depression.	Biological psychiatry	2008	136
18824000	6532	Murphy DL	How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.	Neuropharmacology	2008	61
19439600	6532	Pacheco J	Frontal-limbic white matter pathway associations with the serotonin transporter gene promoter region (5-HTTLPR) polymorphism.	The Journal of neuroscience 	2009	51
20231323	6532	Caspi A	Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits.	The American journal of psychiatry	2010	355
21047622	6532	Homberg JR	Looking on the bright side of serotonin transporter gene variation.	Biological psychiatry	2011	93
22745770	6532	Wang D	Peripheral SLC6A4 DNA methylation is associated with in vivo measures of human brain serotonin synthesis and childhood physical aggression.	PloS one	2012	33
23154100	6532	Bailer UF	Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.	Psychiatry research	2013	25
25086606	6532	Nikolova YS	Beyond genotype: serotonin transporter epigenetic modification predicts human brain function.	Nature neuroscience	2014	31
9331351	6622	Breiter HC	Acute effects of cocaine on human brain activity and emotion.	Neuron	1997	241
9726379	6622	Spillantini MG	Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.	Neuroscience letters	1998	148
10391881	6622	Wood SJ	alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.	The Journal of biological chemistry	1999	122
10678833	6622	Masliah E	Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.	Science	2000	326
10885656	6622	Hamilton RL	Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry.	Brain pathology	2000	106
10991663	6622	Braak H	Pathoanatomy of Parkinson's disease.	Journal of neurology	2000	95
11572944	6622	Masliah E	beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2001	110
11590439	6622	Chung KK	Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.	Nature medicine	2001	138
11923443	6622	Kirik D	Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.	The Journal of neuroscience 	2002	150
12042811	6622	Xu J	Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.	Nature medicine	2002	141
12062037	6622	Giasson BI	Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.	Neuron	2002	239
12122208	6622	Lo Bianco C	alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2002	112
12177198	6622	Sherer TB	An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.	The Journal of neuroscience 	2002	116
12601150	6622	Kirik D	Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2003	82
12714745	6622	Giasson BI	Initiation and synergistic fibrillization of tau and alpha-synuclein.	Science	2003	162
12807436	6622	Lakso M	Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein.	Journal of neurochemistry	2003	82
15473992	6622	Ikonomovic MD	Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury.	Experimental neurology	2004	101
15496679	6622	Fleming SM	Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.	The Journal of neuroscience 	2004	129
15576511	6622	Lo Bianco C	Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	71
15590933	6622	Yavich L	Role of alpha-synuclein in presynaptic dopamine recruitment.	The Journal of neuroscience 	2004	76
15753419	6622	Bennett DA	Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.	Neurology	2005	171
15791003	6622	Zhang W	Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.	FASEB journal 	2005	243
15797547	6622	Yazawa I	Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration.	Neuron	2005	69
15845543	6622	Shin Y	The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways.	The Journal of biological chemistry	2005	81
15851731	6622	Braak H	Cognitive status correlates with neuropathologic stage in Parkinson disease.	Neurology	2005	79
16237129	6622	McKeith IG	Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.	Neurology	2005	841
16399671	6622	Martin LJ	Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.	The Journal of neuroscience 	2006	165
16794039	6622	Cooper AA	Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.	Science	2006	396
17055279	6622	Chu Y	Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?	Neurobiology of disease	2007	95
17166628	6622	Klegeris A	Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia.	Neurobiology of aging	2008	52
17254549	6622	Hoozemans JJ	Activation of the unfolded protein response in Parkinson's disease.	Biochemical and biophysical research communications	2007	87
17537546	6622	Su X	Synuclein activates microglia in a model of Parkinson's disease.	Neurobiology of aging	2008	88
18036154	6622	Reynolds AD	Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease.	Journal of neurochemistry	2008	59
18079166	6622	Orimo S	Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.	Brain 	2008	72
18162487	6622	Fuchs J	Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain.	FASEB journal 	2008	65
18178617	6622	Gorbatyuk OS	The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.	Proceedings of the National Academy of Sciences of the United States of America	2008	73
18245082	6622	Devi L	Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.	The Journal of biological chemistry	2008	180
18291704	6622	Lee HJ	Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.	The international journal of biochemistry and cell biology	2008	130
18451726	6622	Waxman EA	Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.	Journal of neuropathology and experimental neurology	2008	72
18566453	6622	Vogiatzi T	Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells.	The Journal of biological chemistry	2008	145
18704197	6622	Lo Bianco C	Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.	The Journal of clinical investigation	2008	60
18769444	6622	Brundin P	Research in motion: the enigma of Parkinson's disease pathology spread.	Nature reviews. Neuroscience	2008	77
18769546	6622	Tsigelny IF	Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.	PloS one	2008	69
19018246	6622	Theodore S	Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease.	Journal of neuropathology and experimental neurology	2008	64
19074459	6622	Azeredo da Silveira S	Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.	Human molecular genetics	2009	55
19155272	6622	Paleologou KE	Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.	Brain 	2009	46
19230552	6622	Braak H	Neuroanatomy and pathology of sporadic Parkinson's disease.	Advances in anatomy, embryology, and cell biology	2009	49
19273758	6622	Tapiola T	Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.	Archives of neurology	2009	134
19295143	6622	Chung CY	Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.	The Journal of neuroscience 	2009	88
19385059	6622	Cannon JR	A highly reproducible rotenone model of Parkinson's disease.	Neurobiology of disease	2009	96
19436756	6622	Xilouri M	Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.	PloS one	2009	90
19651612	6622	Desplats P	Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein.	Proceedings of the National Academy of Sciences of the United States of America	2009	403
19686384	6622	Danzer KM	Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology.	Journal of neurochemistry	2009	71
19745811	6622	Karpinar DP	Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models.	The EMBO journal	2009	94
19855133	6622	Chen L	Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.	The Journal of clinical investigation	2009	54
19892735	6622	Luk KC	Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	193
19903734	6622	Tong J	Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.	Brain 	2010	40
20038714	6622	Su LJ	Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models.	Disease models and mechanisms	2010	51
20071342	6622	Lee HJ	Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies.	The Journal of biological chemistry	2010	170
20106983	6622	Doxakis E	Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153.	The Journal of biological chemistry	2010	104
20152114	6622	Nemani VM	Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.	Neuron	2010	247
20198645	6622	Li JY	Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease.	Movement disorders 	2010	49
20203178	6622	Paleologou KE	Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.	The Journal of neuroscience 	2010	68
20229352	6622	Del Tredici K	Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease.	Acta neuropathologica	2010	41
20445061	6622	Jowaed A	Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains.	The Journal of neuroscience 	2010	64
20534649	6622	Garcia-Reitböck P	SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.	Brain 	2010	56
20554859	6622	Scott DA	A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration.	The Journal of neuroscience 	2010	81
20599975	6622	Wills J	Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.	Experimental neurology	2010	45
20696318	6622	Oueslati A	Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.	Progress in brain research	2010	67
20856865	6622	Lebouvier T	Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms.	PloS one	2010	65
21488084	6622	Lam HA	Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein.	Journal of neuroscience research	2011	35
21489994	6622	Nakamura K	Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein.	The Journal of biological chemistry	2011	129
21700325	6622	Mazzulli JR	Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.	Cell	2011	216
21766334	6622	Shannon KM	Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.	Movement disorders 	2012	52
21863007	6622	Devine MJ	Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus.	Nature communications	2011	100
22094370	6622	Jain S	Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis.	Neurobiology of disease	2012	35
22110584	6622	Byers B	SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.	PloS one	2011	49
22315227	6622	Fauvet B	α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer.	The Journal of biological chemistry	2012	118
22574141	6622	Maudoux A	Auditory resting-state network connectivity in tinnitus: a functional MRI study.	PloS one	2012	41
22737239	6622	Angot E	Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo.	PloS one	2012	46
22744791	6622	Ebrahimi-Fakhari D	Protein degradation pathways in Parkinson's disease: curse or blessing.	Acta neuropathologica	2012	33
23352769	6622	Mercado G	An ERcentric view of Parkinson's disease.	Trends in molecular medicine	2013	46
23392688	6622	Boassa D	Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis.	The Journal of neuroscience 	2013	35
23526723	6622	Lesage S	G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome.	Annals of neurology	2013	96
23703938	6622	Ulusoy A	Caudo-rostral brain spreading of α-synuclein through vagal connections.	EMBO molecular medicine	2013	29
23739956	6622	Harms AS	MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration.	The Journal of neuroscience 	2013	45
23900411	6622	Irwin DJ	Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.	Nature reviews. Neuroscience	2013	90
23925565	6622	Rey NL	Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice.	Acta neuropathologica	2013	40
24158904	6622	Chung CY	Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons.	Science	2013	76
24243558	6622	Recasens A	Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.	Annals of neurology	2014	73
24382629	6622	Reyes JF	Alpha-synuclein transfers from neurons to oligodendrocytes.	Glia	2014	44
24590631	6622	Asi YT	Alpha-synuclein mRNA expression in oligodendrocytes in MSA.	Glia	2014	24
24788821	6622	Doppler K	Cutaneous neuropathy in Parkinson's disease: a window into brain pathology.	Acta neuropathologica	2014	20
24995389	6622	Seidel K	The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.	Brain pathology	2015	23
25676491	6622	Sengupta U	Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.	Biological psychiatry	2015	20
25732184	6622	Roberts RF	Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.	Brain 	2015	21
26076669	6622	Dettmer U	Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation.	Nature communications	2015	27
26352473	6622	Rodriguez JA	Structure of the toxic core of α-synuclein from invisible crystals.	Nature	2015	44
26446103	6622	Uchihara T	Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.	Acta neuropathologica	2016	17
26564470	6622	Deas E	Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease.	Antioxidants and redox signaling	2016	16
26808899	6622	Theillet FX	Structural disorder of monomeric α-synuclein persists in mammalian cells.	Nature	2016	37
27015771	6622	Stokholm MG	Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients.	Annals of neurology	2016	11
27018801	6622	Tuttle MD	Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein.	Nature structural and molecular biology	2016	34
8209258	6647	Gurney ME	Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.	Science	1994	776
10195180	6647	Williamson TL	Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons.	Nature neuroscience	1999	122
11331366	6647	Pramatarova A	Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment.	The Journal of neuroscience 	2001	88
12050154	6647	Mattiazzi M	Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice.	The Journal of biological chemistry	2002	133
15233913	6647	Liu J	Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria.	Neuron	2004	132
15758154	6647	Vijayvergiya C	Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice.	The Journal of neuroscience 	2005	67
15911875	6647	Kieran D	A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice.	The Journal of cell biology	2005	78
16806844	6647	Van Den Bosch L	The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis.	Biochimica et biophysica acta	2006	69
17038899	6647	Xu L	Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats.	Transplantation	2006	63
17435754	6647	Di Giorgio FP	Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model.	Nature neuroscience	2007	244
18282652	6647	Turner BJ	Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.	Progress in neurobiology	2008	144
18469020	6647	Vucic S	Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis.	Brain 	2008	77
18945894	6647	van Zundert B	Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis.	The Journal of neuroscience 	2008	53
19041780	6647	Di Giorgio FP	Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation.	Cell stem cell	2008	148
19041781	6647	Marchetto MC	Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells.	Cell stem cell	2008	146
19672969	6647	Zhao W	Extracellular mutant SOD1 induces microglial-mediated motoneuron injury.	Glia	2010	59
19914330	6647	Padurariu M	Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease.	Neuroscience letters	2010	44
19951898	6647	Ilieva H	Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond.	The Journal of cell biology	2009	309
19969067	6647	Barber SC	Oxidative stress in ALS: key role in motor neuron injury and therapeutic target.	Free radical biology and medicine	2010	95
20111867	6647	Kerman A	Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form.	Acta neuropathologica	2010	52
20223753	6647	Wong M	Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice.	Human molecular genetics	2010	74
20644736	6647	Forsberg K	Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients.	PloS one	2010	86
21411657	6647	Ozdinler PH	Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G⁹³A transgenic ALS mice.	The Journal of neuroscience 	2011	49
21832997	6647	Haidet-Phillips AM	Astrocytes from familial and sporadic ALS patients are toxic to motor neurons.	Nature biotechnology	2011	186
21908873	6647	Ferraiuolo L	Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis.	Brain 	2011	37
21969586	6647	Papadeas ST	Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2011	55
22219285	6647	Magrané J	Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons.	The Journal of neuroscience 	2012	41
22416121	6647	Guareschi S	An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1.	Proceedings of the National Academy of Sciences of the United States of America	2012	52
23026746	6647	Graffmo KS	Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis.	Human molecular genetics	2013	30
24008656	6647	Foust KD	Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS.	Molecular therapy 	2013	39
24508385	6647	Re DB	Necroptosis drives motor neuron death in models of both sporadic and familial ALS.	Neuron	2014	65
9733503	6863	Kramer MS	Distinct mechanism for antidepressant activity by blockade of central substance P receptors.	Science	1998	103
16078356	6863	Mease P	Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment.	The Journal of rheumatology. Supplement	2005	68
17446239	6863	Suri S	Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis.	Annals of the rheumatic diseases	2007	55
21852280	6863	Anand P	Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch.	British journal of anaesthesia	2011	49
10725386	7442	Mezey E	Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human.	Proceedings of the National Academy of Sciences of the United States of America	2000	143
11992116	7442	Trevisani M	Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1.	Nature neuroscience	2002	85
15124026	7442	Karai L	Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control.	The Journal of clinical investigation	2004	87
15615864	7442	Gavva NR	AMG 9810 (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzob1,4 dioxin-6-yl)acrylamide, a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties.	The Journal of pharmacology and experimental therapeutics	2005	86
17590514	7442	Ruparel NB	Homologous and heterologous desensitization of capsaicin and mustard oil responses utilize different cellular pathways in nociceptors.	Pain	2008	53
18000030	7442	Taylor-Clark TE	Prostaglandin-induced activation of nociceptive neurons via direct interaction with transient receptor potential A1 (TRPA1).	Molecular pharmacology	2008	83
21315593	7442	Everaerts W	The capsaicin receptor TRPV1 is a crucial mediator of the noxious effects of mustard oil.	Current biology 	2011	51
25420066	7442	Wainger BJ	Modeling pain in vitro using nociceptor neurons reprogrammed from fibroblasts.	Nature neuroscience	2015	24
16140383	8266	Wojtkowski M	Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography.	Ophthalmology	2005	155
1486461	9463	Hodges JR	Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy.	Brain 	1992	212
11708987	9463	McKhann GM	Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.	Archives of neurology	2001	285
15349867	9463	Hodges JR	Clinicopathological correlates in frontotemporal dementia.	Annals of neurology	2004	124
17187353	9463	Seeley WW	Early frontotemporal dementia targets neurons unique to apes and humans.	Annals of neurology	2006	69
19725834	9463	Martínez A	Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates.	Brain pathology	2010	48
20110609	9463	Kim W	Interneuronal transfer of human tau between Lamprey central neurons in situ.	Journal of Alzheimer's disease 	2010	45
12848929	10215	Ross SE	Basic helix-loop-helix factors in cortical development.	Neuron	2003	147
15198128	10215	Ligon KL	The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.	Journal of neuropathology and experimental neurology	2004	111
15303102	10215	Aston C	Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder.	Molecular psychiatry	2005	105
16652341	10215	Ligon KL	Olig gene function in CNS development and disease.	Glia	2006	69
16682644	10215	Ligon KL	Development of NG2 neural progenitor cells requires Olig gene function.	Proceedings of the National Academy of Sciences of the United States of America	2006	75
17360586	10215	Nait-Oumesmar B	Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors.	Proceedings of the National Academy of Sciences of the United States of America	2007	77
18515322	10215	Kuhlmann T	Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis.	Brain 	2008	148
19486010	10215	Geha S	NG2+/Olig2+ cells are the major cycle-related cell population of the adult human normal brain.	Brain pathology	2010	42
19696748	10215	Hu BY	Differentiation of spinal motor neurons from pluripotent human stem cells.	Nature protocols	2009	80
19834476	10215	Hu BY	Differentiation of human oligodendrocytes from pluripotent stem cells.	Nature protocols	2009	66
21382551	10215	Sun Y	Phosphorylation state of Olig2 regulates proliferation of neural progenitors.	Neuron	2011	39
22901811	10215	Wang Y	ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.	Cell	2012	32
23395447	10215	Wang S	Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.	Cell stem cell	2013	118
25254339	10215	Douvaras P	Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells.	Stem cell reports	2014	34
10692449	10242	Brenner R	Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4.	The Journal of biological chemistry	2000	175
12783266	10242	Hogg RC	Nicotinic acetylcholine receptors: from structure to brain function.	Reviews of physiology, biochemistry and pharmacology	2003	99
16928859	10242	Staley JK	Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers.	The Journal of neuroscience 	2006	84
19237679	10242	Licht CM	Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension.	Hypertension	2009	48
19647494	10242	Light AR	Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects.	The journal of pain 	2009	47
2324310	10687	Curcio CA	Human photoreceptor topography.	The Journal of comparative neurology	1990	374
10869059	10687	Gultekin SH	Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.	Brain 	2000	121
22451162	10687	Quek AM	Autoimmune epilepsy: clinical characteristics and response to immunotherapy.	Archives of neurology	2012	41
22539258	10687	Bien CG	Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis.	Brain 	2012	63
12446870	11315	Bonifati V	Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.	Science	2003	510
14662519	11315	Bandopadhyay R	The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease.	Brain 	2004	84
15502874	11315	Shendelman S	DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation.	PLoS biology	2004	129
15766664	11315	Kim RH	DJ-1, a novel regulator of the tumor suppressor PTEN.	Cancer cell	2005	125
16227205	11315	Zhou W	DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity.	The Journal of biological chemistry	2005	93
16517609	11315	Choi J	Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases.	The Journal of biological chemistry	2006	109
20639397	11315	Irrcher I	Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics.	Human molecular genetics	2010	108
22523093	11315	Lee JY	Human DJ-1 and its homologs are novel glyoxalases.	Human molecular genetics	2012	36
23462481	11315	Puschmann A	Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations.	Parkinsonism and related disorders	2013	41
19874574	11337	Tabakoff B	Genetical genomic determinants of alcohol consumption in rats and humans.	BMC biology	2009	80
23143228	11337	Brockington A	Unravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity.	Acta neuropathologica	2013	27
25904555	11337	Yuan H	Ionotropic GABA and Glutamate Receptor Mutations and Human Neurologic Diseases.	Molecular pharmacology	2015	27
26040720	11337	Khaminets A	Regulation of endoplasmic reticulum turnover by selective autophagy.	Nature	2015	57
14519670	23336	El-Agnaf OM	Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.	FASEB journal 	2003	128
19195496	23336	Klein A	Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration.	NeuroImage	2009	479
19318117	23336	Nathanson JL	Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors.	Neuroscience	2009	74
20500090	23336	Auluck PK	α-Synuclein: membrane interactions and toxicity in Parkinson's disease.	Annual review of cell and developmental biology	2010	137
21245577	23336	Hansen C	α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.	The Journal of clinical investigation	2011	209
21310920	23336	Yin L	Intravitreal injection of AAV2 transduces macaque inner retina.	Investigative ophthalmology and visual science	2011	42
23506036	23336	Sanchez-Guajardo V	Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity.	ASN neuro	2013	30
23744071	23336	Prots I	α-Synuclein oligomers impair neuronal microtubule-kinesin interplay.	The Journal of biological chemistry	2013	26
24728187	23336	Fares MB	The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.	Human molecular genetics	2014	28
24879923	23336	Tustison NJ	Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements.	NeuroImage	2014	48
25416158	23336	Harischandra DS	α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.	Toxicological sciences 	2015	17
17084815	23435	Arai T	TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.	Biochemical and biophysical research communications	2006	487
17219193	23435	Davidson Y	Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43.	Acta neuropathologica	2007	85
17279000	23435	Neumann M	TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations.	Journal of neuropathology and experimental neurology	2007	92
17481916	23435	Strong MJ	TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein.	Molecular and cellular neurosciences	2007	96
18396105	23435	Van Deerlin VM	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.	The Lancet. Neurology	2008	203
18434538	23435	Johnson BS	A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity.	Proceedings of the National Academy of Sciences of the United States of America	2008	148
18474740	23435	Geser F	Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis.	Archives of neurology	2008	73
18520774	23435	Uryu K	Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.	Journal of neuropathology and experimental neurology	2008	100
18546284	23435	Hasegawa M	Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.	Annals of neurology	2008	128
18723524	23435	Rademakers R	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.	Human molecular genetics	2008	97
18845250	23435	Kimonis VE	VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder.	Biochimica et biophysica acta	2008	57
19021630	23435	Nelson PT	Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons.	Brain pathology	2010	78
19139911	23435	Arai T	Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.	Acta neuropathologica	2009	70
19191304	23435	Rothstein JD	Current hypotheses for the underlying biology of amyotrophic lateral sclerosis.	Annals of neurology	2009	189
19192301	23435	Wijesekera LC	Amyotrophic lateral sclerosis.	Orphanet journal of rare diseases	2009	133
19204154	23435	Geser F	Clinical and pathological continuum of multisystem TDP-43 proteinopathies.	Archives of neurology	2009	80
19271105	23435	Geser F	Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases.	Journal of neurology	2009	56
19465477	23435	Johnson BS	TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity.	The Journal of biological chemistry	2009	182
19515851	23435	Nonaka T	Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43.	Human molecular genetics	2009	82
19765185	23435	Colombrita C	TDP-43 is recruited to stress granules in conditions of oxidative insult.	Journal of neurochemistry	2009	125
19781077	23435	Lu Y	Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching.	Molecular brain	2009	57
19833869	23435	Wegorzewska I	TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2009	190
19959528	23435	Kabashi E	Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo.	Human molecular genetics	2010	120
20154090	23435	Hanson KA	Ubiquilin modifies TDP-43 toxicity in a Drosophila model of amyotrophic lateral sclerosis (ALS).	The Journal of biological chemistry	2010	56
20369906	23435	Rabinovici GD	Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.	CNS drugs	2010	49
20530643	23435	Ash PE	Neurotoxic effects of TDP-43 overexpression in C. elegans.	Human molecular genetics	2010	71
20740007	23435	Elden AC	Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.	Nature	2010	238
20971753	23435	Seelaar H	Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review.	Journal of neurology, neurosurgery, and psychiatry	2011	88
21172843	23435	Rohrer JD	TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia.	Neurology	2010	41
21209826	23435	Yang C	The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism.	PloS one	2010	42
21346515	23435	Pao WC	Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically.	Alzheimer disease and associated disorders	2011	37
21355045	23435	Zhang T	TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling.	Human molecular genetics	2011	36
21421050	23435	Xiao S	RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS.	Molecular and cellular neurosciences	2011	42
21541367	23435	Sun Z	Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS.	PLoS biology	2011	119
21908392	23435	Leyton CE	Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging.	Brain 	2011	47
21989245	23435	Andersen PM	Clinical genetics of amyotrophic lateral sclerosis: what do we really know?	Nature reviews. Neurology	2011	128
22029574	23435	Xu YF	Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice.	Molecular neurodegeneration	2011	44
22120149	23435	Robinson JL	Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old.	Brain 	2011	36
22156203	23435	Huang C	Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats.	The Journal of clinical investigation	2012	30
22427648	23435	Colombrita C	TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells.	The Journal of biological chemistry	2012	52
22445064	23435	King OD	The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.	Brain research	2012	159
22451909	23435	Bilican B	Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability.	Proceedings of the National Academy of Sciences of the United States of America	2012	96
22493728	23435	Pokrishevsky E	Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis.	PloS one	2012	43
22563080	23435	Bentmann E	Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).	The Journal of biological chemistry	2012	63
22855461	23435	Egawa N	Drug screening for ALS using patient-specific induced pluripotent stem cells.	Science translational medicine	2012	119
23012333	23435	Hornberger M	In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease.	Brain 	2012	32
23104007	23435	Armakola M	Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.	Nature genetics	2012	35
23380910	23435	Irwin DJ	Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone.	JAMA neurology	2013	43
23401527	23435	Serio A	Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy.	Proceedings of the National Academy of Sciences of the United States of America	2013	67
23475817	23435	McMillan CT	White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration.	Journal of neurology, neurosurgery, and psychiatry	2013	29
23831027	23435	Nonaka T	Prion-like properties of pathological TDP-43 aggregates from diseased brains.	Cell reports	2013	62
23864344	23435	Nelson PT	Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease.	Acta neuropathologica	2013	43
23891805	23435	Burkhardt MF	A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells.	Molecular and cellular neurosciences	2013	50
23900071	23435	Janssens J	Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.	Human molecular genetics	2013	33
23900711	23435	Kovacs GG	Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series.	Acta neuropathologica	2013	39
24080705	23435	Wilson RS	TDP-43 pathology, cognitive decline, and dementia in old age.	JAMA neurology	2013	41
24240737	23435	Josephs KA	Staging TDP-43 pathology in Alzheimer's disease.	Acta neuropathologica	2014	35
24252435	23435	Toledo JB	Clinical and multimodal biomarker correlates of ADNI neuropathological findings.	Acta neuropathologica communications	2013	26
24439375	23435	Jackrel ME	Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.	Cell	2014	42
24574501	23435	Mesulam MM	Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia.	Brain 	2014	40
24746362	23435	Pasanen P	Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology.	Neurobiology of aging	2014	54
10677483	23621	Lin X	Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.	Proceedings of the National Academy of Sciences of the United States of America	2000	156
12112088	23621	Holsinger RM	Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease.	Annals of neurology	2002	151
14978286	23621	Li R	Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.	Proceedings of the National Academy of Sciences of the United States of America	2004	134
16407166	23621	Sastre M	Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.	Proceedings of the National Academy of Sciences of the United States of America	2006	92
17287498	23621	Xie Z	The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation.	The Journal of neuroscience 	2007	74
17576410	23621	Kim DY	BACE1 regulates voltage-gated sodium channels and neuronal activity.	Nature cell biology	2007	101
17826768	23621	Uryu K	Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans.	Experimental neurology	2007	95
18434550	23621	Hébert SS	Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.	Proceedings of the National Academy of Sciences of the United States of America	2008	298
19006075	23621	Xie Z	The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo.	Annals of neurology	2008	89
19815015	23621	Hampel H	Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.	Experimental neurology	2010	41
20041192	23621	Hemming ML	Identification of beta-secretase (BACE1) substrates using quantitative proteomics.	PloS one	2009	62
20507594	23621	Faghihi MA	Evidence for natural antisense transcript-mediated inhibition of microRNA function.	Genome biology	2010	101
21329555	23621	Chen CH	Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.	The international journal of neuropsychopharmacology	2012	35
22090477	23621	May PC	Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.	The Journal of neuroscience 	2011	79
22285895	23621	Delay C	MicroRNAs in Alzheimer's disease.	Neurobiology of disease	2012	43
24352696	23621	Long JM	MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects.	The Journal of biological chemistry	2014	21
10624965	26047	Poliak S	Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels.	Neuron	1999	125
16473933	26047	Inda MC	Voltage-gated ion channels in the axon initial segment of human cortical pyramidal cells and their relationship with chandelier cells.	Proceedings of the National Academy of Sciences of the United States of America	2006	66
16571880	26047	Strauss KA	Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2.	The New England journal of medicine	2006	166
18179893	26047	Alarcón M	Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene.	American journal of human genetics	2008	274
18179895	26047	Bakkaloglu B	Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders.	American journal of human genetics	2008	184
19896112	26047	Zweier C	CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like mental retardation and determine the level of a common synaptic protein in Drosophila.	American journal of human genetics	2009	98
21048216	26047	Scott-Van Zeeland AA	Altered functional connectivity in frontal lobe circuits is associated with variation in the autism risk gene CNTNAP2.	Science translational medicine	2010	75
21387375	26047	Lancaster E	Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia.	Annals of neurology	2011	81
22473710	26047	Irani SR	Morvan syndrome: clinical and serological observations in 29 cases.	Annals of neurology	2012	55
23407760	26047	Klein CJ	Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.	JAMA neurology	2013	26
23714751	26047	Rodenas-Cuadrado P	Shining a light on CNTNAP2: complex functions to complex disorders.	European journal of human genetics 	2014	40
16275808	27185	Cannon TD	Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory.	Archives of general psychiatry	2005	98
16959794	27185	Hashimoto R	Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling.	Human molecular genetics	2006	72
19716984	27185	Lodge DJ	Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia.	Behavioural brain research	2009	60
19805229	27185	Nakata K	DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms.	Proceedings of the National Academy of Sciences of the United States of America	2009	58
20048751	27185	Ayhan Y	Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders.	Molecular psychiatry	2011	70
20512377	27185	Allman JM	The von Economo neurons in frontoinsular and anterior cingulate cortex in great apes and humans.	Brain structure and function	2010	67
22099458	27185	Singh KK	Common DISC1 polymorphisms disrupt Wnt/GSK3β signaling and brain development.	Neuron	2011	37
25132547	27185	Wen Z	Synaptic dysregulation in a human iPS cell model of mental disorders.	Nature	2014	89
10667797	57142	GrandPré T	Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein.	Nature	2000	210
11170305	57142	Menon V	Error-related brain activation during a Go/NoGo response inhibition task.	Human brain mapping	2001	206
11201742	57142	Fournier AE	Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration.	Nature	2001	228
15950000	57142	Aron AR	The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder.	Biological psychiatry	2005	134
16699079	57142	Picton TW	Effects of focal frontal lesions on response inhibition.	Cerebral cortex	2007	73
17300757	57142	Waltz JA	Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction.	Biological psychiatry	2007	113
18939997	57142	Swick D	Left inferior frontal gyrus is critical for response inhibition.	BMC neuroscience	2008	110
18980476	57142	Rowland JW	Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon.	Neurosurgical focus	2008	100
19308934	57142	Mazaheri A	Prestimulus alpha and mu activity predicts failure to inhibit motor responses.	Human brain mapping	2009	49
20035509	57142	Ballanger B	Stimulation of the subthalamic nucleus and impulsivity: release your horses.	Annals of neurology	2009	59
21399712	57142	Tottenham N	Elevated amygdala response to faces following early deprivation.	Developmental science	2011	97
21876169	57142	Casey BJ	Behavioral and neural correlates of delay of gratification 40 years later.	Proceedings of the National Academy of Sciences of the United States of America	2011	90
23020899	57142	Jovanovic T	Reduced neural activation during an inhibition task is associated with impaired fear inhibition in a traumatized civilian sample.	Cortex; a journal devoted to the study of the nervous system and behavior	2013	30
23498139	57142	Silveri MM	Frontal lobe γ-aminobutyric acid levels during adolescence: associations with impulsivity and response inhibition.	Biological psychiatry	2013	27
25891220	57142	Gyurak A	Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.	Biological psychiatry	2016	12
12595101	78996	Bammer R	Basic principles of diffusion-weighted imaging.	European journal of radiology	2003	80
17598166	78996	Horovitz SG	Low frequency BOLD fluctuations during resting wakefulness and light sleep: a simultaneous EEG-fMRI study.	Human brain mapping	2008	162
17686438	78996	Nir Y	Coupling between neuronal firing rate, gamma LFP, and BOLD fMRI is related to interneuronal correlations.	Current biology 	2007	142
18439825	78996	Goense JB	Neurophysiology of the BOLD fMRI signal in awake monkeys.	Current biology 	2008	153
18927326	78996	Hofmann M	MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration.	Journal of nuclear medicine 	2008	56
20057496	78996	Zhang D	Disease and the brain's dark energy.	Nature reviews. Neurology	2010	229
20372169	78996	Chen JJ	Global cerebral oxidative metabolism during hypercapnia and hypocapnia in humans: implications for BOLD fMRI.	Journal of cerebral blood flow and metabolism 	2010	52
21931738	78996	Zotev V	Self-regulation of amygdala activation using real-time FMRI neurofeedback.	PloS one	2011	52
23623973	78996	Griffa A	Structural connectomics in brain diseases.	NeuroImage	2013	52
17320141	94233	Gamlin PD	Human and macaque pupil responses driven by melanopsin-containing retinal ganglion cells.	Vision research	2007	98
18054803	94233	Hankins MW	Melanopsin: an exciting photopigment.	Trends in neurosciences	2008	64
18836071	94233	Lin B	Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin.	Proceedings of the National Academy of Sciences of the United States of America	2008	74
19850061	94233	McDougal DH	The influence of intrinsically-photosensitive retinal ganglion cells on the spectral sensitivity and response dynamics of the human pupillary light reflex.	Vision research	2010	49
20463367	94233	Gooley JJ	Spectral responses of the human circadian system depend on the irradiance and duration of exposure to light.	Science translational medicine	2010	52
20471354	94233	Lall GS	Distinct contributions of rod, cone, and melanopsin photoreceptors to encoding irradiance.	Neuron	2010	78
20959623	94233	Do MT	Intrinsically photosensitive retinal ganglion cells.	Physiological reviews	2010	81
21743008	94233	Park JC	Toward a clinical protocol for assessing rod, cone, and melanopsin contributions to the human pupil response.	Investigative ophthalmology and visual science	2011	40
21816493	94233	Schmidt TM	Intrinsically photosensitive retinal ganglion cells: many subtypes, diverse functions.	Trends in neurosciences	2011	87
22633808	94233	Brown TM	Melanopsin-based brightness discrimination in mice and humans.	Current biology 	2012	36
23554393	94233	Bailes HJ	Human melanopsin forms a pigment maximally sensitive to blue light (λmax ≈ 479 nm) supporting activation of G(q/11) and G(i/o) signalling cascades.	Proceedings. Biological sciences	2013	32
26505992	94233	La Morgia C	Melanopsin retinal ganglion cell loss in Alzheimer disease.	Annals of neurology	2016	16
15680457	120892	Gilks WP	A common LRRK2 mutation in idiopathic Parkinson's disease.	Lancet	2005	151
16272164	120892	Khan NL	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.	Brain 	2005	73
16437559	120892	Ross OA	Lrrk2 and Lewy body disease.	Annals of neurology	2006	64
16437584	120892	Giasson BI	Biochemical and pathological characterization of Lrrk2.	Annals of neurology	2006	67
16750377	120892	Greggio E	Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.	Neurobiology of disease	2006	227
17120249	120892	Biskup S	Localization of LRRK2 to membranous and vesicular structures in mammalian brain.	Annals of neurology	2006	178
17341485	120892	Hatano T	Leucine-rich repeat kinase 2 associates with lipid rafts.	Human molecular genetics	2007	59
18445495	120892	Shin N	LRRK2 regulates synaptic vesicle endocytosis.	Experimental cell research	2008	101
18701920	120892	Imai Y	Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila.	The EMBO journal	2008	161
19545277	120892	Gillardon F	Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?	Journal of neurochemistry	2009	76
19625511	120892	Saha S	LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans.	The Journal of neuroscience 	2009	73
19640926	120892	Alegre-Abarrategui J	LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.	Human molecular genetics	2009	138
20386743	120892	Xiong Y	GTPase activity plays a key role in the pathobiology of LRRK2.	PLoS genetics	2010	69
20642453	120892	Nichols RJ	14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.	The Biochemical journal	2010	89
20659558	120892	Melrose HL	Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.	Neurobiology of disease	2010	81
20876399	120892	Meixner A	A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics.	Molecular and cellular proteomics 	2011	36
21159966	120892	Lee S	LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction.	The Journal of neuroscience 	2010	48
21168496	120892	Winner B	Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice.	Neurobiology of disease	2011	50
21248115	120892	Dusonchet J	A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.	The Journal of neuroscience 	2011	44
21362567	120892	Nguyen HN	LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.	Cell stem cell	2011	178
21494637	120892	Ramonet D	Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.	PloS one	2011	96
22342962	120892	Gillardon F	Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.	Neuroscience	2012	38
22363216	120892	Stafa K	GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.	PLoS genetics	2012	40
22407749	120892	Sánchez-Danés A	Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.	EMBO molecular medicine	2012	98
22764206	120892	Cooper O	Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.	Science translational medicine	2012	100
23125283	120892	Cho HJ	MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.	Human molecular genetics	2013	30
23472874	120892	Reinhardt P	Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.	Cell stem cell	2013	82
23533608	120892	Reinhardt P	Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling.	PloS one	2013	34
23916833	120892	Manzoni C	Inhibition of LRRK2 kinase activity stimulates macroautophagy.	Biochimica et biophysica acta	2013	27
24403142	120892	Skibinski G	Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.	The Journal of neuroscience 	2014	32
24682598	120892	Schapansky J	Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.	Human molecular genetics	2014	23
25080504	120892	Gómez-Suaga P	LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity.	Human molecular genetics	2014	21
15629698	121278	Zhang X	Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression.	Neuron	2005	82
17241888	121278	Gershon MD	The serotonin signaling system: from basic understanding to drug development for functional GI disorders.	Gastroenterology	2007	226
19120094	121278	Lowry CA	Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus.	Annals of the New York Academy of Sciences	2008	66
20124538	121278	Duncan JR	Brainstem serotonergic deficiency in sudden infant death syndrome.	JAMA	2010	84
9809557	146713	Eriksson PS	Neurogenesis in the adult human hippocampus.	Nature medicine	1998	976
10915564	146713	Sanchez-Ramos J	Adult bone marrow stromal cells differentiate into neural cells in vitro.	Experimental neurology	2000	221
10931522	146713	Woodbury D	Adult rat and human bone marrow stromal cells differentiate into neurons.	Journal of neuroscience research	2000	363
11220740	146713	Kordower JH	Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment.	Annals of neurology	2001	95
12051722	146713	Safford KM	Neurogenic differentiation of murine and human adipose-derived stromal cells.	Biochemical and biophysical research communications	2002	94
18442397	146713	Jiang Y	Isolation of neuronal chromatin from brain tissue.	BMC neuroscience	2008	68
19226510	146713	Azevedo FA	Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain.	The Journal of comparative neurology	2009	231
19606083	146713	Boldrini M	Antidepressants increase neural progenitor cells in the human hippocampus.	Neuropsychopharmacology 	2009	157
21646517	146713	Kohler SJ	Maturation time of new granule cells in the dentate gyrus of adult macaque monkeys exceeds six months.	Proceedings of the National Academy of Sciences of the United States of America	2011	38
22338017	146713	Christie LA	Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy.	Clinical cancer research 	2012	36
22083254	203228	Murray ME	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.	Acta neuropathologica	2011	97
22101323	203228	Al-Sarraj S	p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.	Acta neuropathologica	2011	132
22105541	203228	Ince PG	Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology.	Acta neuropathologica	2011	45
22181065	203228	Troakes C	An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline.	Neuropathology 	2012	40
22228244	203228	Stewart H	Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p.	Acta neuropathologica	2012	46
22300873	203228	Snowden JS	Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations.	Brain 	2012	112
22300876	203228	Simón-Sánchez J	The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions.	Brain 	2012	73
22305801	203228	Byrne S	Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study.	The Lancet. Neurology	2012	89
22366792	203228	Cooper-Knock J	Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.	Brain 	2012	71
22366795	203228	Whitwell JL	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics.	Brain 	2012	95
22875087	203228	Sha SJ	Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features.	Neurology	2012	36
23117491	203228	Irwin DJ	Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis.	Journal of neurology, neurosurgery, and psychiatry	2013	29
23381195	203228	Mori K	hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations.	Acta neuropathologica	2013	91
23393093	203228	Mori K	The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS.	Science	2013	233
23720273	203228	Ciura S	Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis.	Annals of neurology	2013	71
23818065	203228	Fratta P	Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia.	Acta neuropathologica	2013	34
23836290	203228	Almeida S	Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons.	Acta neuropathologica	2013	92
24011653	203228	van Blitterswijk M	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study.	The Lancet. Neurology	2013	51
24170860	203228	Lagier-Tourenne C	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2013	110
24248382	203228	Zu T	RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia.	Proceedings of the National Academy of Sciences of the United States of America	2013	116
24252525	203228	Mann DM	Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72.	Acta neuropathologica communications	2013	40
24379375	203228	Meyer K	Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS.	Proceedings of the National Academy of Sciences of the United States of America	2014	64
24394885	203228	Gendron TF	Mechanisms of toxicity in C9FTLD/ALS.	Acta neuropathologica	2014	32
24493408	203228	Cooper-Knock J	The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype.	Acta neuropathologica	2014	27
24559645	203228	Waite AJ	Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion.	Neurobiology of aging	2014	38
24598541	203228	Haeusler AR	C9orf72 nucleotide repeat structures initiate molecular cascades of disease.	Nature	2014	155
24703839	203228	Wainger BJ	Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons.	Cell reports	2014	94
24704492	203228	Kiskinis E	Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1.	Cell stem cell	2014	83
25081482	203228	Kwon I	Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells.	Science	2014	95
25120191	203228	May S	C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration.	Acta neuropathologica	2014	51
25132468	203228	Su Z	Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS.	Neuron	2014	53
25173361	203228	Zhang YJ	Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress.	Acta neuropathologica	2014	54
25398948	203228	Yamakawa M	Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS.	Human molecular genetics	2015	25
25521377	203228	Wen X	Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death.	Neuron	2014	61
25580746	203228	Devlin AC	Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability.	Nature communications	2015	34
25662776	203228	Rohrer JD	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis.	The Lancet. Neurology	2015	30
26085200	203228	Schludi MH	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing.	Acta neuropathologica	2015	29
26150098	203228	Maizels N	G4-associated human diseases.	EMBO reports	2015	29
26308891	203228	Zhang K	The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.	Nature	2015	105
26308899	203228	Freibaum BD	GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport.	Nature	2015	94
26637797	203228	Peters OM	Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice.	Neuron	2015	27
26989253	203228	O'Rourke JG	C9orf72 is required for proper macrophage and microglial function in mice.	Science	2016	51
27334615	203228	Webster CP	The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy.	The EMBO journal	2016	23
21294650	100506658	Carrano A	Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy.	Antioxidants and redox signaling	2011	45
21909359	100506658	Biron KE	Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease.	PloS one	2011	49
22197032	100506658	Xu R	HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9.	Brain research	2012	37
